[
  {
    "objectID": "diarrhea.html#infectious-diarrheal-diseases",
    "href": "diarrhea.html#infectious-diarrheal-diseases",
    "title": "Infectious Diarrheal Diseases",
    "section": "Infectious Diarrheal Diseases",
    "text": "Infectious Diarrheal Diseases\n\n\nRussell Lewis  Associate Professor, Infectious Diseases  Department of Molecular Medicine  MEP 2491 Infectious Diseases  27 March 2023"
  },
  {
    "objectID": "diarrhea.html#objectives",
    "href": "diarrhea.html#objectives",
    "title": "Infectious Diarrheal Diseases",
    "section": "Objectives",
    "text": "Objectives\n\n\nIdentify the most common causes of infectious diarrhea in adult patients in resource-rich settings\nDescribe how the patient history and clinical presentation of diarrhea may favour viral versus bacterial causes that benefit from antibiotic therapy\nRecognize warning signs for severe diarrheal disease that require immediate hospitalization and/or antibiotic therapy\nDescribe management approach and treatment of common infectious diarrheal pathogens\nWe will not be discussing (in detail) diarrheal diseases in resource-poor countries. Information on these infections should be obtained from the WHO guidelines"
  },
  {
    "objectID": "diarrhea.html#background",
    "href": "diarrhea.html#background",
    "title": "Infectious Diarrheal Diseases",
    "section": "Background",
    "text": "Background\n\n\nDiarrheal disease is one of the top ten leading causes of death worldwide\nDiarrheal disease is a particular concern for children younger than five years old in resource-limited settings\nAmong adults in resource-rich settings, diarrhea is often a “nuisance disease” in the healthy individual\nMost cases of acute diarrhea in adults are of infectious etiology, and most cases resolve with symptomatic treatment alone\nWhen clinicians care for adults with diarrhea, two important decision points are:\n\nWhen to perform stool testing\nWhether to initiate empiric antimicrobial therapy\n\n\n\n\n(GBD 2016 Diarrhoeal Disease Collaborators, 2018; Shane et al., 2017)"
  },
  {
    "objectID": "diarrhea.html#definitions",
    "href": "diarrhea.html#definitions",
    "title": "Infectious Diarrheal Diseases",
    "section": "Definitions",
    "text": "Definitions\n\n\n\nDiarrhea is defined as the passage of loose or watery stools, typically at least three times in a 24-hour period\nReflects increased water content of the stool, whether due to impaired water absorption and/or active water secretion by the bowel\n\nAcute – 14 days or fewer in duration\nPersistent diarrhea – more than 14 but fewer than 30 days in duration\nChronic – more than 30 days in duration\n\nInvasive diarrhea, dysentery- diarrhea with visible blood or mucous\n\nDysentery is commonly associated with fever and abdominal pain"
  },
  {
    "objectID": "diarrhea.html#etiology",
    "href": "diarrhea.html#etiology",
    "title": "Infectious Diarrheal Diseases",
    "section": "Etiology",
    "text": "Etiology\n \n\nMost cases of acute diarrhea are due to infections and are self-limited\nMost cases of acute infectious diarrhea are viral, as indicated by the observation that stool cultures are positive in only 1.5 to 5.6 % of cases\nThe major causes of acute infectious diarrhea include:\n\nViruses (norovirus, rotavirus, adenoviruses, astrovirus, and others)\nBacteria (Salmonella, Campylobacter, Shigella, enterotoxigenic Escherichia coli, Clostridioides difficile, and others)\nProtozoa (Cryptosporidium, Giardia, Cyclospora, Entamoeba, and others)\n\n\n\n\n(Dryden et al., 1996)"
  },
  {
    "objectID": "diarrhea.html#causes-of-acute-infectious-diarrhea-in-adults-in-resource-rich-settings",
    "href": "diarrhea.html#causes-of-acute-infectious-diarrhea-in-adults-in-resource-rich-settings",
    "title": "Infectious Diarrheal Diseases",
    "section": "Causes of acute infectious diarrhea in adults in resource-rich settings",
    "text": "Causes of acute infectious diarrhea in adults in resource-rich settings\n \n\n\n\n\n\n\n\n\n\n\n\nLikely pathogens\nMean incubation period\nClassic/ common food sources\nOther epidemiologic clues\n\n\n\n\nWatery diarrhea\nNorovirus\n24 to 48 hours\n-Shellfish, prepared foods, vegetables, fruit\nOutbreaks in: - Restaurants - Health care facilities - Schools and childcare centers - Cruise ships - Military populations\n\n\nClostridioides (formerly Clostridium difficile)\nN/A\nN/A\nAntibiotic use- Hospitalization- Cancer chemotherapy- Gastric acid suppression- Inflammatory bowel disease\n\n\n\nClostridium perfringens\n8 to 16 hours\nMeat, poultry, gravy, home-canned goods\n\n\n\n\nEnterotoxigenic Escherichia coli (ETEC)\n1 to 3 days\nFecally contaminated food or water\n-Travel to resource-limited settings\n\n\n\nOther enteric viruses (rotavirus, enteric adenovirus, astrovirus, sapovirus)\n10 to 72 hours\nFecally contaminated food or water\n-Daycare centers -Gastroenteritis in children -Immunocompromised adults\n\n\n\nGiardia lamblia\n7 to 14 days\nFecally contaminated food or water\n-Daycare centers -Swimming pools -Travel, hiking, camping (particularly when there is contact with water in which beavers reside)\n\n\n\nCryptosporidium parvum\n2 to 28 days\nVegetables, fruit, unpasteurized milk\n-Daycare centers-Swimming pools and recreational water sources- Animal exposure -Chronic diarrhea in advanced HIV infection\n\n\n\nListeria monocytogenes\n1 day (gastroenteritis)\nProcessed/delicatessen meats, hot dogs, soft cheese, pâtés, and fruit\n-Pregnancy-Immunocompromising condition-Extremes of age\n\n\n\nCyclospora cayetanensis\n1 to 11 days\nImported berries, herbs\n-Chronic diarrhea in advanced HIV infection\n\n\n\nInflammatory diarrhea (fever, mucoid or bloody stools)¶\nNontyphoidal Salmonella\n1 to 3 days\n-Poultry, eggs, and egg products, fresh produce, meat, fish, unpasteurized milk or juice, nut butters, spices\n-Animal contact (petting zoos, reptiles, live poultry, other pets)-Travel to resource-limited settings\n\n\nCampylobacter spp\n1 to 3 days\nPoultry, meat, unpasteurized milk\n-Travel to resource-limited settings -Animal contact (young puppies or kittens, occupational contact)\n\n\n\nShigella spp\n1 to 3 days\nRaw vegetables\n-Daycare centers Crowded living conditions -Men who have sex with men -Travel to resource-limited settings\n\n\n\nEnterohemorrhagic E. coli (EHEC)\n1 to 8 days\nGround beef and other meat, fresh produce, unpasteurized milk and juice\n-Daycare centers -Nursing homes -Extremes of age\n\n\n\nYersinia spp\n4 to 6 days\nPork or pork products, untreated water\n-Abnormalities of iron-metabolism (eg, cirrhosis, hemochromatosis, thalassemia) -Blood transfusion\n\n\n\nVibrio parahemolyticus\n1 to 3 days\nRaw seafood and shellfish\nCirrhosis\n\n\n\nEntamoeba histolytica\n1 to 3 weeks\nFecally contaminated food or water\nTravel to resourcelimited settings Men who have sex with men\n\n\n\n\nClostridioides (formerly Clostridium) difficile can also present with inflammatory diarrhea.\n¶ Pathogens that are more classically associated with inflammatory diarrhea can also cause watery diarrhea, particularly early in the course of infection."
  },
  {
    "objectID": "diarrhea.html#references",
    "href": "diarrhea.html#references",
    "title": "Infectious Diarrheal Diseases",
    "section": "References",
    "text": "References\n\n\n\n\n\n\n\nAhmed SM, Hall AJ, Robinson AE, Verhoef L, Premkumar P, Parashar UD, et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. The Lancet Infectious Diseases 2014;14:725–30. https://doi.org/10.1016/s1473-3099(14)70767-4.\n\n\nDryden MS, Gabb RJ, Wright SK. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 1996;22:1019–25. https://doi.org/10.1093/clinids/22.6.1019.\n\n\nGBD 2016 Diarrhoeal Disease Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet Infectious Diseases 2018;18:1211–28. https://doi.org/10.1016/S1473-3099(18)30362-1.\n\n\nRiddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults. The American Journal of Gastroenterology 2016;111:602–22. https://doi.org/10.1038/ajg.2016.126.\n\n\nShane AL, Mody RK, Crump JA, Tarr PI, Steiner TS, Karen L. Kotloff, et al. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clinical Infectious Diseases 2017;65:1963–73. https://doi.org/10.1093/cid/cix669."
  },
  {
    "objectID": "FUO.html#fever-of-unknown-origin-fuo",
    "href": "FUO.html#fever-of-unknown-origin-fuo",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Fever of unknown origin (FUO)",
    "text": "Fever of unknown origin (FUO)\n\n\nRussell Lewis  Associate Professor, Infectious Diseases  Department of Molecular Medicine  MEP 2491 Infectious Diseases  13 March 2023"
  },
  {
    "objectID": "FUO.html#objectives",
    "href": "FUO.html#objectives",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Objectives",
    "text": "Objectives\n\n\nRecognize leading infectious causes of FUO in key patient groups\nIdentify key fever patterns and clinical histories that may direct diagnosis\nDifferentiate FUO risks and possible spectum of pathogens in immunocompromised hosts"
  },
  {
    "objectID": "FUO.html#the-history-of-fever",
    "href": "FUO.html#the-history-of-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "The history of fever",
    "text": "The history of fever\n\n\n\n10th Century BCE Persian Physician Akhawayni defined a system for fever curves in Hidāyat al-Muta’allimīn fī al-Tibb (The Student’s Handbook of Medicine)\nHippocratic physicians proposed that body temperature, and physiologic harmony in general, involved a delicate balance among four corporal humors—blood, phlegm, black bile, and yellow bile.\n\nFever was due to excess of yellow bile (many infections caused jaundice)\n\nGalen: many types of fever developed from putrification of humors.\nMiddle ages: demonic possession\n18th century (Harvey’s discovery of circulation)- friction of blood flow through body causing fermentation and putrification in intestines\nClaude Bernard in the 19th century- metabolic processes in the body"
  },
  {
    "objectID": "FUO.html#febris--roman-goddess-of-fever",
    "href": "FUO.html#febris--roman-goddess-of-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Febris- Roman Goddess of Fever",
    "text": "Febris- Roman Goddess of Fever\n\n\n\nThe legend of Febris was said to center around the haunting marshes of Camagna in Southern Italy where like clockwork every year, the people would become deathly ill with a mysterious disease. She was so feared by the Romans that the suffering population had created a cult to Febris. They went so far as to wear protective amulets and build her temples in order to worship her to win her favour."
  },
  {
    "objectID": "FUO.html#galileo-and-the-room-thermometer-in-padova",
    "href": "FUO.html#galileo-and-the-room-thermometer-in-padova",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Galileo and the room thermometer in Padova",
    "text": "Galileo and the room thermometer in Padova"
  },
  {
    "objectID": "FUO.html#fever-in-modern-medicine",
    "href": "FUO.html#fever-in-modern-medicine",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Fever in modern medicine",
    "text": "Fever in modern medicine\n\nWunderlich’s pioneering studies of thermometry-normal 37°C\nSince the 19th century, humans have become gradually colder-0.05° to 0.5°C per decade\nCurrent normal range is 36.3 to 36.5°C\n\n\n\n(Mackowiak and Worden, 1994)"
  },
  {
    "objectID": "FUO.html#thermal-homeostasis",
    "href": "FUO.html#thermal-homeostasis",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Thermal homeostasis",
    "text": "Thermal homeostasis\n\n\n\n\n\n\n\n(Sajadi, Mohammad M. and Mackowiak, Philip A., n.d.)"
  },
  {
    "objectID": "FUO.html#infection-associated-fever",
    "href": "FUO.html#infection-associated-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Infection-associated fever",
    "text": "Infection-associated fever\n\n\n\n\n\n\n\n(Wright and Auwaerter, 2020)"
  },
  {
    "objectID": "FUO.html#sequelae-of-fever",
    "href": "FUO.html#sequelae-of-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Sequelae of fever",
    "text": "Sequelae of fever\n\n\nPhylogenetic conservation of fever over the millennia suggests fever is beneficial\nMost pathogenic bacteria are mesophiles (35°C ideal for growth)\nFever generates hepatic iron-sequestering compounds the bind free iron necessary for microbial replication"
  },
  {
    "objectID": "FUO.html#acute-phase-proteins",
    "href": "FUO.html#acute-phase-proteins",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Acute phase proteins",
    "text": "Acute phase proteins\n\n\n(Gabay and Kushner, 1999)"
  },
  {
    "objectID": "FUO.html#role-of-acute-phase-proteins",
    "href": "FUO.html#role-of-acute-phase-proteins",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Role of acute phase proteins",
    "text": "Role of acute phase proteins"
  },
  {
    "objectID": "FUO.html#acute-phase-phenomena",
    "href": "FUO.html#acute-phase-phenomena",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Acute phase phenomena",
    "text": "Acute phase phenomena\n\n\n(Gabay and Kushner, 1999)"
  },
  {
    "objectID": "FUO.html#epidemiology-of-fuo--definitions",
    "href": "FUO.html#epidemiology-of-fuo--definitions",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Epidemiology of FUO- Definitions",
    "text": "Epidemiology of FUO- Definitions\n\n\n\n\n\n\n\n(Haidar and Singh, 2022)"
  },
  {
    "objectID": "FUO.html#classic-fuo",
    "href": "FUO.html#classic-fuo",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Classic FUO",
    "text": "Classic FUO\n\n\nDefinition:\n\nTemperature of > 38.3°C > 3 weeks\nFever >2 separate outpatient visits with diagnostic investigations or\nFever >2 visits in hospital of 3 days with diagnostic investigations\n\nHowever, these definitions are largely subjective\n\n\nLeading causes:\n\nInfections (geography dependent)\nInflammatory conditions (age dependent)\nCancer (age dependent)\nUndiagnosed /unknown"
  },
  {
    "objectID": "FUO.html#frequency-of-the-5-main-etiologic-categories-of-fuo",
    "href": "FUO.html#frequency-of-the-5-main-etiologic-categories-of-fuo",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Frequency of the 5 main etiologic categories of FUO",
    "text": "Frequency of the 5 main etiologic categories of FUO\nInfectious causes decrease in patients above age 65 years\n\n\n(Wright, William F. and Mackowiak, Philip A., 2015)"
  },
  {
    "objectID": "FUO.html#classic-fuo--infectious-etiology",
    "href": "FUO.html#classic-fuo--infectious-etiology",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Classic FUO- Infectious Etiology",
    "text": "Classic FUO- Infectious Etiology\n\n\nChronic or relapsing infections\n\nOccult abscess\nEndocarditis\nTuberculosis\nComplicated urinary tract infections\nOsteomyelitis"
  },
  {
    "objectID": "FUO.html#classic-fuo-work-up",
    "href": "FUO.html#classic-fuo-work-up",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Classic FUO work-up",
    "text": "Classic FUO work-up\n\n\n\nMedical history emphasis:\n\nTravel\nContacts\nAnimal and insect exposure\nMedications\nImmunizations\nFamily history\nCardiac valve disorder\n\nExamination emphasis\n\nFundi, oropharynx, temporal artery, abdomen, lymph nodes, spleen, joints, skin, nails, genitalia, rectum or prostate, lower limb deep veins\n\nInvestigation emphasis:\n\nImaging, biopsies, sedimentation rate, skin tests"
  },
  {
    "objectID": "FUO.html#rare-and-miscellaneous-causes-of-fever",
    "href": "FUO.html#rare-and-miscellaneous-causes-of-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Rare and miscellaneous causes of fever",
    "text": "Rare and miscellaneous causes of fever"
  },
  {
    "objectID": "FUO.html#classic-fuo-in-infants-and-children",
    "href": "FUO.html#classic-fuo-in-infants-and-children",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Classic FUO in infants and children",
    "text": "Classic FUO in infants and children\n\n\nRespiratory tract infections\nOther infections: UTIs, brucellosis, tuberculosis, bartonellosis\nKawasaki disease (age < 5 years)\nInflammatory bowel diseases\nStill’s disease (juvenile rheumatoid arthritis)\n\nHowever, connective tissue diseases and cancers are generally rare in children\n\nJoint involvement is an important sign of a potentially serious disorder- e.g., connective tissue disease, endocarditis, leukemia"
  },
  {
    "objectID": "FUO.html#classic-fuo-in-elderly-patients",
    "href": "FUO.html#classic-fuo-in-elderly-patients",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Classic FUO in elderly patients",
    "text": "Classic FUO in elderly patients\n\n\nIn developed countries: connective tissue diseases > infections\n\nTemporal arteritis\nPolymyalgia rheumatic syndromes\n\nDiagnoses are frequently missed because symptoms are subacute and non-specific\nInfections\n\nintraabdominal abscess\nComplicated UTIs\nTuberculosis\nEndocarditis"
  },
  {
    "objectID": "FUO.html#returning-travellers",
    "href": "FUO.html#returning-travellers",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Returning travellers",
    "text": "Returning travellers\n\n\n\n(Wright, William F. and Mackowiak, Philip A., 2015)"
  },
  {
    "objectID": "FUO.html#nosocomial-health-care-associated-fuo",
    "href": "FUO.html#nosocomial-health-care-associated-fuo",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Nosocomial (Health-Care Associated) FUO",
    "text": "Nosocomial (Health-Care Associated) FUO\n\n\nLeading causes:\n\nDrug fever\nPost-operative complications (e.g., occult abscess)\nDecubitus ulcers\nSeptic thrombophlebitis\nRecurrent pulmonary emboli\nMyocardial infarction\nCancer\nBlood transfusion\nReactions to contrast media\nClostridium difficile colitis"
  },
  {
    "objectID": "FUO.html#fever-in-post-operative-patients",
    "href": "FUO.html#fever-in-post-operative-patients",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Fever in post-operative patients",
    "text": "Fever in post-operative patients\n\n\nAlthough more than 1/3 of patients may manifest fever in first 5 days surgery, < 10% of febrile patients have an identified source or positive cultures\nFever may represent a physiological response to surgically-induced tissue injury with release of pyrogenic cytokines and interleukins rather than result of infection"
  },
  {
    "objectID": "FUO.html#fuo-in-icu-patients",
    "href": "FUO.html#fuo-in-icu-patients",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "FUO in ICU patients",
    "text": "FUO in ICU patients\n\n\nEarly fevers are common, often non-infectious, associated with good prognosis\nProlonged fever carries a poorer prognosis\nSinusitis as a complication of mechanical ventilation, supine position, feeding tubes\nOther causes are similar to nosocomial infections in non-ICU patients\n\nAbscess\nDrug fever\nPostoperative complications\nSeptic thrombophlebitis\nRecurrent pulmonary emboli\nMyocardial infarction"
  },
  {
    "objectID": "FUO.html#fuo-in-stroke-patients",
    "href": "FUO.html#fuo-in-stroke-patients",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "FUO in stroke patients",
    "text": "FUO in stroke patients\n\n\nNon-infective fevers are commonly seen in patients with intracranial mass effects and occur earlier after stroke than infection\nUTI are common related to urinary catheterization"
  },
  {
    "objectID": "FUO.html#fuo-in-neutropenic-patients",
    "href": "FUO.html#fuo-in-neutropenic-patients",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "FUO in neutropenic patients",
    "text": "FUO in neutropenic patients\n\n\n\nANC= Total WBC x (% Segs + % Bands)\nNeutropenia is defined as an ANC of < 500 cells/mm3 or an ANC that is expected to decrease to < 500 cells/mm3 during the next 48 h.\n\nThe term “profound” is sometimes used to describe neutropenia in which the ANC is < 100 cells/mm3\n\nFever occurs frequently during chemotherapy-induced neutropenia:\n\n10%–50% of patients with solid tumors\n80% of those with hematologic malignancies will develop fever during >1 chemotherapy cycle associated with neutropenia\n\nMost patients will have no infectious etiology documented.\nSigns of inflammation are notoriously absent other than fever"
  },
  {
    "objectID": "FUO.html#clinical-manifestations-of-infection-related-to-absolute-neutrophil-count-anc",
    "href": "FUO.html#clinical-manifestations-of-infection-related-to-absolute-neutrophil-count-anc",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Clinical manifestations of infection related to absolute neutrophil count (ANC)",
    "text": "Clinical manifestations of infection related to absolute neutrophil count (ANC)\n\n\n\n\n\n\n\n\n\n\nSigns and symptoms\nInfection\n% of patients with ANC< 100\n% of patients with ANC>1000\n\n\n\n\nFever\nOverall\n98\n76\n\n\nBacteremia\nOverall\n43\n13\n\n\nFluctuance\nAnorectal\n8\n67\n\n\nExudate\nSkin\n5\n92\n\n\nPurulent sputum\nPneumonia\n8\n84\n\n\nPyuria\nUTI\n11\n97\n\n\n\n\n\n(Sickles et al., 1975)"
  },
  {
    "objectID": "FUO.html#possible-causes-of-fever-in-neutropenic-patients-not-responding-to-broad-spectrum-antibiotics",
    "href": "FUO.html#possible-causes-of-fever-in-neutropenic-patients-not-responding-to-broad-spectrum-antibiotics",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Possible causes of fever in neutropenic patients not responding to broad-spectrum antibiotics",
    "text": "Possible causes of fever in neutropenic patients not responding to broad-spectrum antibiotics\n\n\n(Corey and Boeckh, 2002)"
  },
  {
    "objectID": "FUO.html#cell-mediated-immunity-1",
    "href": "FUO.html#cell-mediated-immunity-1",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Cell-mediated immunity-1",
    "text": "Cell-mediated immunity-1\n\n\n\n(Playfair, J. and Bancroft, G., 2013)"
  },
  {
    "objectID": "FUO.html#cell-mediated-immunity-2",
    "href": "FUO.html#cell-mediated-immunity-2",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Cell-mediated immunity-2",
    "text": "Cell-mediated immunity-2\n\n\n(Playfair, J. and Bancroft, G., 2013)"
  },
  {
    "objectID": "FUO.html#cell-mediated-immunity-drug-allergy",
    "href": "FUO.html#cell-mediated-immunity-drug-allergy",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Cell-mediated immunity-Drug allergy",
    "text": "Cell-mediated immunity-Drug allergy\n\n\n(Playfair, J. and Bancroft, G., 2013)"
  },
  {
    "objectID": "FUO.html#infections-in-immunocompromised-hosts",
    "href": "FUO.html#infections-in-immunocompromised-hosts",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Infections in immunocompromised hosts",
    "text": "Infections in immunocompromised hosts"
  },
  {
    "objectID": "FUO.html#hiv-related-fuo",
    "href": "FUO.html#hiv-related-fuo",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "HIV-related FUO",
    "text": "HIV-related FUO\n\n\nPrimary phase of infection characterized by mononucleosis-like illness where fever is common, may be undiagnosed if it precedes seroconversion\nIn later phases of untreated HIV, episodes of fever become common and often signify a superimposed illness- e.g., opportunistic infections that manifest in atypical fashion\nOnce highly-active antiretroviral therapy (HAART) is started and HIC viral load is effectively suppressed, the frequency of FUO falls markedly"
  },
  {
    "objectID": "FUO.html#etiology-of-fever-in-hiv-associated-fuo-n70",
    "href": "FUO.html#etiology-of-fever-in-hiv-associated-fuo-n70",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Etiology of fever in HIV-Associated FUO (n=70)",
    "text": "Etiology of fever in HIV-Associated FUO (n=70)\n\n\n\n\n\n\n\n(Wright, William F. and Mackowiak, Philip A., 2015)"
  },
  {
    "objectID": "FUO.html#naproxen-nsiad-fever-suppression-test-for-tumor-fever",
    "href": "FUO.html#naproxen-nsiad-fever-suppression-test-for-tumor-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Naproxen (NSIAD) fever suppression test for “tumor fever”",
    "text": "Naproxen (NSIAD) fever suppression test for “tumor fever”\n\n\nA trial of naproxen may differentiate neoplastic from non-neoplastic fever\n\nTemperature >37.8°C at least once a day;\nDuration of fever >2 weeks;\nLack of evidence of infection (eg physical examination, laboratory examinations, and imaging studies);\nAbsence of allergic mechanisms (eg, drug allergy, transfusion reaction, and radiation or chemotherapeutic drug reaction);\nLack of response of fever to an empiric, adequate antibiotic therapy for at least 7 days;\nPrompt complete lysis by the naproxen test with sustained normal temperature while receiving naproxen."
  },
  {
    "objectID": "FUO.html#diagnosis-of-fuo",
    "href": "FUO.html#diagnosis-of-fuo",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Diagnosis of FUO",
    "text": "Diagnosis of FUO"
  },
  {
    "objectID": "FUO.html#general-diagnostic-evaluation-of-fuo",
    "href": "FUO.html#general-diagnostic-evaluation-of-fuo",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "General diagnostic evaluation of FUO",
    "text": "General diagnostic evaluation of FUO\n\n\n\n\n\n\n\nComprehensive history\n\n\n\n\nRepeated physical exams\n\n\nComplete blood count\n\n\nRoutine blood chemistry\n\n\nUrinalysis including microscopic examination\n\n\nChest radiograph\n\n\nErythrocyte sedimentation rate, C-reactive protein\n\n\nAntinuclear antibodies\n\n\nRheumatoid factor\n\n\nBlood cultures- three separate specimens in the absence of antimicrobial therapy\n\n\nCMV IgM antibodies or viral detection in blood\n\n\nHeterophil antibody test in children and young adults\n\n\nTuberculin skin test\n\n\nComputed tomography of abdomen, pelvis and other sites\n\n\nMRI/Radionucleotide scans\n\n\nHIV antibodies or viral detection assay\n\n\nFurther evaluation of any abnormality detected by above tests\n\n\nVarious duplex imaging of lower limbs\n\n\n\n\n(Wright, William F. and Mackowiak, Philip A., 2015)"
  },
  {
    "objectID": "FUO.html#patient-history",
    "href": "FUO.html#patient-history",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Patient history",
    "text": "Patient history\n\n\n\nHelps guide choice of initial laboratory investigations\nParticular attention should be given to:\n\nRecent travel\nExposure to pets and other animals\nWork environment\nRecent contact with people with similar symptoms\nFamily history (e.g., familial Mediterranean fever)\n\nPrior history of FUO\nPreviously diagnosed conditions\n\nLymphoma\nRheumatic fever\nIntraabdominal disorders\n\nComplete list of medications"
  },
  {
    "objectID": "FUO.html#verification-of-fever-and-fever-pattern",
    "href": "FUO.html#verification-of-fever-and-fever-pattern",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Verification of fever and fever pattern",
    "text": "Verification of fever and fever pattern\n\n\nObvious,… but often overlooked\n\nIn some series, up to 30% referred for FUO where determined to not have fever\n\nFever patterns- arcane terminology:\n\nremittent, intermittent, hectic, quotidian, sustained, quartan, saddleback fevers\n\nFever patterns are affected by:\n\nHydration, ambient temperature\nAccuracy of temperature measurements\nUse of antipyretics, corticosteroids\nBlood transfusions, other medical interventions etc."
  },
  {
    "objectID": "FUO.html#continuous-sustained-fever",
    "href": "FUO.html#continuous-sustained-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Continuous sustained fever",
    "text": "Continuous sustained fever\n\n\nContinuous (sustained) fever with slight remission not exceed 2°C\n\nLobar and Gram negative pneumonia\nRickettsiosis\nTyphoid fever\nCNS disorders\nTularemia\nFalciparum (malignant tertian) malaria\n\n\n\n\n\n\n\n\n\n(Mackowiak et al., 1997)"
  },
  {
    "objectID": "FUO.html#malaria-fever",
    "href": "FUO.html#malaria-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Malaria fever",
    "text": "Malaria fever\n\nFebrile paroxysms may occur every other day for P. vivax, P. ovale, and P. falciparum and every third day for P. malariae. Paroxysms occurring at regular intervals are more common in the setting of infection due to P. vivax or P. ovale than P. falciparum. With improvements in early diagnosis and treatment, this traditional description of cyclic fever is seen infrequently."
  },
  {
    "objectID": "FUO.html#intermittent-fever",
    "href": "FUO.html#intermittent-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Intermittent fever",
    "text": "Intermittent fever\n\n\nIntermittent (septic, quotidian, “picket fence”) fever with wide fluctuations, usually normal or low in the morning and peaking between 4:00 and 8:00 PM\n\nLocalized pyogenic infections and bacterial endocarditis with chills and leukocytosis\nMalaria (often with leukopenia) may present with daily (quotidian) daily spike or (tertian) spike every 3rd day, or (quartan) spike every 4th day.\nDouble quotidian patter (two daily spikes) seen with salmonellosis, miliary tuberculosis, double malarial infections (more than one species), gonococcal and meningococcal endocarditis\n\n\n\n\n(Mackowiak et al., 1997)"
  },
  {
    "objectID": "FUO.html#saddle-back-biphasic",
    "href": "FUO.html#saddle-back-biphasic",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Saddle-back (biphasic)",
    "text": "Saddle-back (biphasic)\n\n\nSeveral days of fever, distinct reduction in fever for ~ 1 day, and then several days of higher fever\n\nDengue and yellow fever\nColorado tick fever\nRift valley Fever\nInfluenzae and other viral infections\n\n\n\n\n\n\n\n\n\n(Mackowiak et al., 1997)"
  },
  {
    "objectID": "FUO.html#intermittent-hectic-charcots-fever",
    "href": "FUO.html#intermittent-hectic-charcots-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Intermittent hectic (Charcot’s) fever",
    "text": "Intermittent hectic (Charcot’s) fever\n\n\nSporadic episodes of fever, periods of normal temperature with recurrence\n\nFrequently seen in cholangitis associated with cholelithiasis, jaundice, leukocytosis and toxic signs\n\n\n\n\n(Mackowiak et al., 1997)"
  },
  {
    "objectID": "FUO.html#pel-ebstein-fever",
    "href": "FUO.html#pel-ebstein-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Pel-Ebstein fever",
    "text": "Pel-Ebstein fever\n\n\nWeekly or longer periods of fever and equally long afebrile periods, with repetition of the cycle\n\nHodgkin’s disease\nBrucellosis due to Brucella melitensis\nOccasionally tuberculosis\n\n\n\n\n\n\n\n\n\n(Mackowiak et al., 1997)"
  },
  {
    "objectID": "FUO.html#typus-inversus",
    "href": "FUO.html#typus-inversus",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Typus Inversus",
    "text": "Typus Inversus\n\n\nReversal of diurnal pattern, with highest temperatures in the early morning hours rather than during the late afternoon or evening\n\nMiliary TB\nSalmonelloses\nHepatic abscess\nBacterial endocarditis\n\n\n\n\n(Mackowiak et al., 1997)"
  },
  {
    "objectID": "FUO.html#typhoid-fever",
    "href": "FUO.html#typhoid-fever",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Typhoid fever",
    "text": "Typhoid fever"
  },
  {
    "objectID": "FUO.html#jarisch-herxheimer-reaction",
    "href": "FUO.html#jarisch-herxheimer-reaction",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Jarisch-Herxheimer reaction",
    "text": "Jarisch-Herxheimer reaction\n\n\n\nSharply increased elevation of temperature with shivers and chills occurs within several hours after starting penicillin therapy\nLysis of spirochetes\n\nPrimary or secondary syphilis; Leptospirosis; or tick-borne relapsing fever\nTetracycline or chloramphenicol therapy for acute brucellosis\n\n\n\n\n(Mackowiak et al., 1997)"
  },
  {
    "objectID": "FUO.html#physical-examination",
    "href": "FUO.html#physical-examination",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Physical examination",
    "text": "Physical examination\n\nSome signs are subtle and may require repeated exams to be appreciated\nVigorous search for lymphadenopathy (consideration for biopsy)\n\n\n\n(Wright, William F. and Mackowiak, Philip A., 2015)"
  },
  {
    "objectID": "FUO.html#laboratory-investigations",
    "href": "FUO.html#laboratory-investigations",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Laboratory investigations",
    "text": "Laboratory investigations\n\n“The cause is more often a common disease presenting in an atypical fashion than a rare disease presenting in a typical fashion.\n\nMultiple diagnostic algorithms in the literature\nMust be selectively applied or will result in excessive unfocused diagnositc testing\n\nFalse positives\nMisguided treatment plans\n\nHistory and physical exam (most important) should guide the choice and sequence of tests"
  },
  {
    "objectID": "FUO.html#examples-of-potential-diagnostic-clues",
    "href": "FUO.html#examples-of-potential-diagnostic-clues",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Examples of potential diagnostic clues",
    "text": "Examples of potential diagnostic clues\n\n\n(Wright, William F. and Mackowiak, Philip A., 2015)"
  },
  {
    "objectID": "FUO.html#bone-marrow-biopsy",
    "href": "FUO.html#bone-marrow-biopsy",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Bone marrow biopsy",
    "text": "Bone marrow biopsy\n\n\nGranulomatous infections (e.g., tuberculosis, histoplasmosis, sarcoidosis)\nPatients with abnormal complete blood counts (CBC)"
  },
  {
    "objectID": "FUO.html#imaging-studies",
    "href": "FUO.html#imaging-studies",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Imaging studies",
    "text": "Imaging studies\n\n\nGenerally low diagnostic yield without localizing symptoms\n\nCT of abdomen, chest\nUltrasound of gallbladder and hepatobiliary systems\nCT pulmonary angiograms for pulmonary embolus\nMRI for CNS, abdomen spleen and lymph nodes Aortic arch and proximal cervical arteries (vasculitis)\nThe indium 111- tagged white blood cell (WBC) scan (becoming less comon)\nGallium-67 (67Ga) scan (replaced by PET-CT)"
  },
  {
    "objectID": "FUO.html#f-fluorodeoxyglucose-fdg-positron-emission-tomography-pet",
    "href": "FUO.html#f-fluorodeoxyglucose-fdg-positron-emission-tomography-pet",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)",
    "text": "18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)\n\n\n\n(de Kleijn et al., 1997; Wright et al., 2021)"
  },
  {
    "objectID": "FUO.html#f-fluorodeoxyglucose-fdg-positron-emission-tomography-pet-1",
    "href": "FUO.html#f-fluorodeoxyglucose-fdg-positron-emission-tomography-pet-1",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "F-fluorodeoxyglucose (FDG) positron emission tomography (PET)",
    "text": "F-fluorodeoxyglucose (FDG) positron emission tomography (PET)\n\n\n\n(Kouijzer et al., 2018)"
  },
  {
    "objectID": "FUO.html#invasive-diagnostic-procedures",
    "href": "FUO.html#invasive-diagnostic-procedures",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Invasive diagnostic procedures",
    "text": "Invasive diagnostic procedures\n \n\nHistopathological examination of tissues obtained by excisional biopsy , needle biopsy or laparotomy can provide definitive diagnosis in some cases\nMajority of FUO patients will undergo at least one procedure"
  },
  {
    "objectID": "FUO.html#treatment",
    "href": "FUO.html#treatment",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Treatment",
    "text": "Treatment\n\n\nA fundamental principle in classic FUO is that therapy should be withheld until the cause of fever is determined\n\nNon-specific treatment rarely “cures” FUO\nEmpiric treatment may delay the clinical diagnosis\n\nClinical reality is that therapeutic trials with corticosteroids, aspirin, antimicrobial agents may be considered\n\nMay delay correct diagnosis/treatment\nThe road to diagnosis of FUO is, by definition, long and frustrating\nClinicians are often pressured to treat symptoms"
  },
  {
    "objectID": "FUO.html#diagnostic-summary",
    "href": "FUO.html#diagnostic-summary",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Diagnostic summary",
    "text": "Diagnostic summary\n\n\n(Wright and Auwaerter, 2020)"
  },
  {
    "objectID": "FUO.html#when-is-immediate-treatment-indicated",
    "href": "FUO.html#when-is-immediate-treatment-indicated",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "When is immediate treatment indicated?",
    "text": "When is immediate treatment indicated?\n\n\nEmpirical treatment with corticosteroids in patients with suspected temporal arteritis to prevent vascular complications such as blindness and stroke\nFebrile neutropenia or other severely immunocompromised patients: high prevalence of serious bacterial infections- patients should receive broad-spectrum antimicrobial therapy with anti-pseudomonas coverage after appropriate cultures are obtained\nTherapeutic trials with narrow spectrum therapy (e.g. anti-mycobacterial agents) may be considered in select cases with history suggestive of TB"
  },
  {
    "objectID": "FUO.html#prognosis",
    "href": "FUO.html#prognosis",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Prognosis",
    "text": "Prognosis\n\n\nDetermined y the cause of fever and nature of underlying disease(s)\nElderly patients with malignant neoplasms have the poorest prognosis\nDiagnostic delay associated with poorer prognosis in:\n\nIntra-abdominal infections\nMiliary tuberculosis\nDisseminated fungal infections\nRecurrent pulmonary emboli\n\nPatients with undiagnosed FUO after extensive evaluation still generally have a a favourable outcome, with most patients experiencing resolution of fever within 4 weeks without sequlae.\n\n5-year mortality rates of 3%"
  },
  {
    "objectID": "FUO.html#references",
    "href": "FUO.html#references",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "References",
    "text": "References\n\n\n\n\n\n\nCorey L, Boeckh M. Persistent fever in patients with neutropenia. The New England Journal of Medicine 2002;346:222–4. https://doi.org/10.1056/NEJM200201243460402.\n\n\nde Kleijn EM, Vandenbroucke JP, van der Meer JW. Fever of unknown origin (FUO). I A. Prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria. The Netherlands FUO Study Group. Medicine 1997;76:392–400. https://doi.org/10.1097/00005792-199711000-00002.\n\n\nGabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. The New England Journal of Medicine 1999;340:448–54. https://doi.org/10.1056/NEJM199902113400607.\n\n\nHaidar G, Singh N. Fever of Unknown Origin. New England Journal of Medicine 2022;386:463–77. https://doi.org/10.1056/NEJMra2111003.\n\n\nKouijzer IJE, Mulders-Manders CM, Bleeker-Rovers CP, Oyen WJG. Fever of Unknown Origin: The Value of FDG-PET/CT. Seminars in Nuclear Medicine 2018;48:100–7. https://doi.org/10.1053/j.semnuclmed.2017.11.004.\n\n\nMackowiak PA, Bartlett JG, Borden EC, Goldblum SE, Hasday JD, Munford RS, et al. Concepts of Fever: Recent Advances and Lingering Dogma. Clinical Infectious Diseases 1997;25:119–38.\n\n\nMackowiak PA, Worden G. Carl Reinhold August Wunderlich and the evolution of clinical thermometry. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 1994;18:458–67. https://doi.org/10.1093/clinids/18.3.458.\n\n\nPlayfair, J., Bancroft, G. Infection and Immunity, 4th Edition. Oxford University Press; 2013.\n\n\nSajadi, Mohammad M., Mackowiak, Philip A. Temperature Regulation and the Pathogenesis of Fever. Principles and Practice of Infectious Diseases, 8th Edition, Elsevier Health Sciences; n.d., p. 4739–452.\n\n\nSickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Archives of Internal Medicine 1975;135:715–9.\n\n\nWright WF, Auwaerter PG. Fever and Fever of Unknown Origin: Review, Recent Advances, and Lingering Dogma. Open Forum Infectious Diseases 2020;7:ofaa132. https://doi.org/10.1093/ofid/ofaa132.\n\n\nWright WF, Auwaerter PG, Dibble EH, Rowe SP, Mackowiak PA. Imaging a Fever-Redefining the Role of 2-deoxy-2-[18F]Fluoro-D-Glucose-Positron Emission Tomography/Computed Tomography in Fever of Unknown Origin Investigations. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2021;72:1279–86. https://doi.org/10.1093/cid/ciaa1220.\n\n\nWright, William F., Mackowiak, Philip A. Principles and Practice of Infectious Diseases, 8th Edition. Fever of Unknown Origin, Elsevier Health Sciences; 2015."
  },
  {
    "objectID": "Index.html#welcome",
    "href": "Index.html#welcome",
    "title": "ME2491 Infectious Diseases",
    "section": "Welcome",
    "text": "Welcome\nWelcome to the ME2491 Medicine and Surgery INFECTIOUS DISEASES educational resources page.\nUsing the navigation bar on the right, you can find links to reading, educational websites, podcasts, and online antibiotic dosing models that will be of interest as you progress through the course.\nCore course materials will also be posted on the University Moodle Course site when activated."
  },
  {
    "objectID": "febrileneutropenia.html",
    "href": "febrileneutropenia.html",
    "title": "Febrile neutropenia",
    "section": "",
    "text": "slides"
  },
  {
    "objectID": "febrileneutropenia.html#nccn-guidelines",
    "href": "febrileneutropenia.html#nccn-guidelines",
    "title": "Febrile neutropenia",
    "section": "2022 NCCN Guidelines",
    "text": "2022 NCCN Guidelines\nNCCN guidelines\nProphylaxis recommendations\nPodcast episode on febrile neutroopenia"
  },
  {
    "objectID": "IFI.html",
    "href": "IFI.html",
    "title": "Invasive Fungal Infections",
    "section": "",
    "text": "slides\nReview article on antifungal agents agents\nTissue penetration of antifungals\nReview article on antifungal susceptibility testing\nReview on invasive candidiasis\nReview on invasive aspergillosis\nReview on cryptococcosis"
  },
  {
    "objectID": "Resistance.html",
    "href": "Resistance.html",
    "title": "Antimicrobial Resitance in ESCAPE Pathogens",
    "section": "",
    "text": "A PDF copy of lecture slides can be downloaded here"
  },
  {
    "objectID": "Resistance.html#background-reading",
    "href": "Resistance.html#background-reading",
    "title": "Antimicrobial Resitance in ESCAPE Pathogens",
    "section": "Background reading",
    "text": "Background reading\nRecent comprehensive review of antimicrobial resistance in ESKAPE pathogens ESKAPE review\nInfectious Diseases Society of America Guidelines for Treating ESBL, CRE and Pseudomonas IDSA1\nInfectious Diseases Society of America Guidelines for Treating AMP-C beta-lactamases, Carbapenem-resistant Acinetobacter spp. and Stenotrophomonas IDSA2\nESCMID Guidelines for treatment of MDR Gram-Negative Organisms ESCMID\nExcellent review on AMP-C resistance AMP-C\nExcellent review on role of new antibiotics for carbapenem-resistant pathogens new agents"
  },
  {
    "objectID": "FUOpage.html",
    "href": "FUOpage.html",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "",
    "text": "Lecture slides can be accessed here\nPDF version of the slides can be downloaded here"
  },
  {
    "objectID": "FUOpage.html#background-reading",
    "href": "FUOpage.html#background-reading",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Background reading:",
    "text": "Background reading:\nRecent review on FUO in NEJM  Excellent review on FUO in OFID  Classic review on fever patterns and classic FUO Dogma"
  },
  {
    "objectID": "FUOpage.html#fuo-podcast",
    "href": "FUOpage.html#fuo-podcast",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "FUO podcast",
    "text": "FUO podcast\nFebrile’s podcast episode on FUO"
  },
  {
    "objectID": "FUOpage.html#online-lecture",
    "href": "FUOpage.html#online-lecture",
    "title": "Fever of Unknown Origin (FUO)",
    "section": "Online lecture",
    "text": "Online lecture\nFever of Unknown Origin (FUO) with Dr. Raghuram\nIN this online lecture, Dr. Raghuram takes a look at traditional and new definitions of FUOs as well as a practical algorithm for their workup.She takes a comprehensive look at common non-infectious causes including often used drugs that can produce fevers in patients. Dr. Raghuram finishes with several cases presented in a board review style and walks through her thought process with evaluating the questions.\nFe"
  },
  {
    "objectID": "immunosuppression.html#infections-in-the-immunocompromised-host-febrile-neutropenia",
    "href": "immunosuppression.html#infections-in-the-immunocompromised-host-febrile-neutropenia",
    "title": "Infections in the Immunocompromised Host",
    "section": "",
    "text": "Russell Lewis  Associate Professor, Infectious Diseases  Department of Molecular Medicine  MEP 2491 Infectious Diseases  13 March 2023"
  },
  {
    "objectID": "immunosuppression.html#objectives",
    "href": "immunosuppression.html#objectives",
    "title": "Parasitic Infections: Malaria and Leishamoniasis",
    "section": "Objectives",
    "text": "Objectives"
  },
  {
    "objectID": "immunosuppression.html#microbial-colonization",
    "href": "immunosuppression.html#microbial-colonization",
    "title": "Infections in the Immunocompromised Host",
    "section": "Microbial colonization",
    "text": "Microbial colonization"
  },
  {
    "objectID": "immunosuppression.html#healthy-hosts",
    "href": "immunosuppression.html#healthy-hosts",
    "title": "Infections in the Immunocompromised Host",
    "section": "Healthy hosts",
    "text": "Healthy hosts\n\n\nProtection against most pathogens through complex and redundant network of:\n\nProtective surfaces\nCells (e.g., granulocytes, macrophages, NK cells)\nSoluble factors (antibody, complement)\nResident microbiota (competition for binding sites and available nutrients as well as shaping the immune system)"
  },
  {
    "objectID": "immunosuppression.html#classification-of-the-immunosuppressed-host",
    "href": "immunosuppression.html#classification-of-the-immunosuppressed-host",
    "title": "Infections in the Immunocompromised Host",
    "section": "Classification of the immunosuppressed host",
    "text": "Classification of the immunosuppressed host"
  },
  {
    "objectID": "immunosuppression.html#deficiencies-in-host-defences",
    "href": "immunosuppression.html#deficiencies-in-host-defences",
    "title": "Infections in the Immunocompromised Host",
    "section": "Deficiencies in host defences",
    "text": "Deficiencies in host defences\n\n\nAlthough certain organisms can infect patients with specific immune defects, it is not always predictable\nBasic patterns are recognizable, but the types and severity of complications is often unpredictable\n\nSingle, isolated deficiencies are the exception rather than the rule\nMultiple defence mechanisms are often affected\n\ne.g., chemotherapy → mucosal barrier injury + neutropenia\ne.g., stem cell transplantation → chemotherapy → immunosuppressive therapy + delayed reconstitution of adaptive immunity + graft versus host disease (GVHD)"
  },
  {
    "objectID": "immunosuppression.html#innate-immune-system",
    "href": "immunosuppression.html#innate-immune-system",
    "title": "Infections in the Immunocompromised Host",
    "section": "Innate immune system",
    "text": "Innate immune system\n\n\n\n\n\n\nPlayfair and Bancroft. Infection and Immunity 4th Edition"
  },
  {
    "objectID": "immunosuppression.html#effector-mechanisms-and-targets-of-the-innate-immune-system",
    "href": "immunosuppression.html#effector-mechanisms-and-targets-of-the-innate-immune-system",
    "title": "Infections in the Immunocompromised Host",
    "section": "Effector mechanisms and targets of the innate immune system",
    "text": "Effector mechanisms and targets of the innate immune system"
  },
  {
    "objectID": "immunosuppression.html#chemotherapy-effects-on-granulocytes",
    "href": "immunosuppression.html#chemotherapy-effects-on-granulocytes",
    "title": "Infections in the Immunocompromised Host",
    "section": "Chemotherapy effects on granulocytes",
    "text": "Chemotherapy effects on granulocytes\n\n\n\nVirtually all antineoplastic drugs in the treatment of malignant diseases have a deleterious effect on the proliferation of normal hematopoietic progenitor cells\nEffects are enhanced by radiation (depending on dose, rate, site)\n\nObliteration of the mitotic pool\nDepletion of the marrow reserve\n\nAntineoplastic drugs, glucocorticoids and irradiation also interfere with the function of non-proliferating granulocytes, resulting in\n\nDecreased chemotaxis\nDiminished phagocytic capacity\nDefective intracellular killing\n\nGlucocorticoids seem to enhance granulocytopoiesis and mobilize the marginal and marrow pool reserve, but\n\nreduce accumulation of granuloytes at site of infection (reduced adherence)\ndiminished chemotactic activity\ndecreased phagocytosis and intracellular killing"
  },
  {
    "objectID": "immunosuppression.html#granulocytopenia",
    "href": "immunosuppression.html#granulocytopenia",
    "title": "Infections in the Immunocompromised Host",
    "section": "Granulocytopenia",
    "text": "Granulocytopenia\n\nInfection rateFatality rate\n\n\n  (Bodey et al., 1966)\n\n\n  (Bodey et al., 1966)"
  },
  {
    "objectID": "immunosuppression.html#clinical-manifestations-of-infection-related-to-absolute-neutrophil-count-anc",
    "href": "immunosuppression.html#clinical-manifestations-of-infection-related-to-absolute-neutrophil-count-anc",
    "title": "Infections in the Immunocompromised Host",
    "section": "Clinical manifestations of infection related to absolute neutrophil count (ANC)",
    "text": "Clinical manifestations of infection related to absolute neutrophil count (ANC)\n\n\n\n\n\n\n\n\n\n\nSigns and symptoms\nInfection\n% of patients with ANC&lt; 100\n% of patients with ANC&gt;1000\n\n\n\n\nFever\nOverall\n98\n76\n\n\nBacteremia\nOverall\n43\n13\n\n\nFluctuance\nAnorectal\n8\n67\n\n\nExudate\nSkin\n5\n92\n\n\nPurulent sputum\nPneumonia\n8\n84\n\n\nPyuria\nUTI\n11\n97\n\n\n\n\n\n(Sickles et al., 1975)"
  },
  {
    "objectID": "immunosuppression.html#typical-antimicrobial-flora",
    "href": "immunosuppression.html#typical-antimicrobial-flora",
    "title": "Infections in the Immunocompromised Host",
    "section": "Typical antimicrobial flora",
    "text": "Typical antimicrobial flora"
  },
  {
    "objectID": "immunosuppression.html#infection-model",
    "href": "immunosuppression.html#infection-model",
    "title": "Infections in the Immunocompromised Host",
    "section": "Infection model",
    "text": "Infection model"
  },
  {
    "objectID": "immunosuppression.html#microbiologically-defined-bacterial-infections",
    "href": "immunosuppression.html#microbiologically-defined-bacterial-infections",
    "title": "Infections in the Immunocompromised Host",
    "section": "Microbiologically defined bacterial infections",
    "text": "Microbiologically defined bacterial infections"
  },
  {
    "objectID": "immunosuppression.html#immunodeficiencies-and-assocaited-pathogens-1",
    "href": "immunosuppression.html#immunodeficiencies-and-assocaited-pathogens-1",
    "title": "Infections in the Immunocompromised Host",
    "section": "Immunodeficiencies and assocaited pathogens #1",
    "text": "Immunodeficiencies and assocaited pathogens #1"
  },
  {
    "objectID": "immunosuppression.html#types-of-infection-versus-phases-of-neutropenia",
    "href": "immunosuppression.html#types-of-infection-versus-phases-of-neutropenia",
    "title": "Infections in the Immunocompromised Host",
    "section": "Types of infection versus phases of neutropenia",
    "text": "Types of infection versus phases of neutropenia"
  },
  {
    "objectID": "immunosuppression.html#prolonged-neutropenia-is-a-risk-for-invasive-mold-disease",
    "href": "immunosuppression.html#prolonged-neutropenia-is-a-risk-for-invasive-mold-disease",
    "title": "Infections in the Immunocompromised Host",
    "section": "Prolonged neutropenia is a risk for invasive mold disease",
    "text": "Prolonged neutropenia is a risk for invasive mold disease"
  },
  {
    "objectID": "immunosuppression.html#references",
    "href": "immunosuppression.html#references",
    "title": "Infections in the Immunocompromised Host",
    "section": "References",
    "text": "References\n\n\n\n\n\n\nBodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine 1966;64:328–40.\n\n\nSickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Archives of Internal Medicine 1975;135:715–9."
  },
  {
    "objectID": "Allergies.html",
    "href": "Allergies.html",
    "title": "Antibiotic allergies",
    "section": "",
    "text": "Lecture slides can be downloaded here\nEssential review on diagnosing and managing penicillin allergies\nThe following links below may require access via University proxy. Click on the the “multimedia” link to find the videos and podcasts.\nJAMA Educational Videos and Podcasts on Evaulating, Manging and Testing Penicillin Allergies\nWhat every new doctor should know about adverse drug reactions\nExcellent and entertaining dicussion on PCN de-labeling\nPatient information on PCN allergy testing\nAmoxicillin challenge forms"
  },
  {
    "objectID": "Antibiotic.html",
    "href": "Antibiotic.html",
    "title": "Principles of Antibiotic Therapy",
    "section": "",
    "text": "A PDF copy of lecture slides can be downloaded here"
  },
  {
    "objectID": "Antibiotic.html#background-reading",
    "href": "Antibiotic.html#background-reading",
    "title": "Principles of Antibiotic Therapy",
    "section": "Background reading",
    "text": "Background reading\nAlthough published in 2011, this paper remains the highest-cited general review on Principles of Antibiotic Treatment\nClassic Antibiotic PK/PD Review\nSome information out of date, but this is a Classic Antibiotic PK/PD Review from the “father” of the field, Dr. William Craig, M.D.\nPK/PD and TDM Position Paper\nRecent review on antimicrobial susceptibiltiy testing methods\nIDSA Clinical Microbiology Guidelines 2018\nEUCAST Website"
  },
  {
    "objectID": "Antibiotic.html#links-to-prof.-sebastian-wichas-online-precision-antibiotic-dosing-models",
    "href": "Antibiotic.html#links-to-prof.-sebastian-wichas-online-precision-antibiotic-dosing-models",
    "title": "Principles of Antibiotic Therapy",
    "section": "Links to Prof. Sebastian Wicha’s online precision antibiotic dosing models",
    "text": "Links to Prof. Sebastian Wicha’s online precision antibiotic dosing models\nClick on this link: TDMx\n Note: The UNIPD Proxy may block the TDMx landing page for the models, but individual drug model pages demonstrated in class still seemed to be accessible through the proxy:\nGentamicin  Vancomycin  Meropenem"
  },
  {
    "objectID": "diarrhea.html#evaluation-of-acute-diarrhea-in-adults",
    "href": "diarrhea.html#evaluation-of-acute-diarrhea-in-adults",
    "title": "Infectious Diarrheal Diseases",
    "section": "Evaluation of acute diarrhea in adults",
    "text": "Evaluation of acute diarrhea in adults\n\n\n\n\n\n\n\n(Riddle et al., 2016)"
  },
  {
    "objectID": "diarrhea.html#evaluation",
    "href": "diarrhea.html#evaluation",
    "title": "Infectious Diarrhea",
    "section": "Evaluation",
    "text": "Evaluation"
  },
  {
    "objectID": "diarrhea.html#when-does-the-patient-need-to-be-seen-in-clinic",
    "href": "diarrhea.html#when-does-the-patient-need-to-be-seen-in-clinic",
    "title": "Infectious Diarrhea",
    "section": "When does the patient need to be seen in clinic?",
    "text": "When does the patient need to be seen in clinic?\n\nPersistent fever, bloody diarrhea, severe abdominal pain, symptoms of volume depletion (eg, dark or scant urine, symptoms of orthostasis), or a history of inflammatory bowel disease\nHospitalization required when:\n\nHistory of immunosuppression (e.g., tratment for malignancy, transplantation, HIV\nSignificant cardiovascular diseases"
  },
  {
    "objectID": "diarrhea.html#when-should-patient-be-evaluated-in-clinic",
    "href": "diarrhea.html#when-should-patient-be-evaluated-in-clinic",
    "title": "Infectious Diarrheal Diseases",
    "section": "When should patient be evaluated in clinic?",
    "text": "When should patient be evaluated in clinic?"
  },
  {
    "objectID": "diarrhea.html#patient-medical-history",
    "href": "diarrhea.html#patient-medical-history",
    "title": "Infectious Diarrheal Diseases",
    "section": "Patient Medical History",
    "text": "Patient Medical History\n\n\n\n\n\n\n\n(Shane et al., 2017)"
  },
  {
    "objectID": "diarrhea.html#exxposures",
    "href": "diarrhea.html#exxposures",
    "title": "Infectious Diarrhea",
    "section": "Exxposures",
    "text": "Exxposures"
  },
  {
    "objectID": "diarrhea.html#exposures",
    "href": "diarrhea.html#exposures",
    "title": "Infectious Diarrhea",
    "section": "Exposures",
    "text": "Exposures\n\nFood history, residence, occupational exposure, recent and remote travel, pets, and hobbies, can also provide further diagnostic clues."
  },
  {
    "objectID": "diarrhea.html#enteric-pathogens",
    "href": "diarrhea.html#enteric-pathogens",
    "title": "Infectious Diarrhea",
    "section": "Enteric pathogens",
    "text": "Enteric pathogens\n\n\n\n\n\n\n\n\n\nPathogen\nSmall bowel\nColon\n\n\n\n\nBacteria\nSalmonellaEscherichia coli¶Clostridium perfringensStaphylococcus aureusAeromonas hydrophilaBacillus cereusVibrio cholerae\nCampylobacterShigellaClostridioides difficileYersiniaVibrio parahaemolyticusEnteroinvasive E. coliPlesiomonas shigelloidesKlebsiella oxytoca (rare)\n\n\nVirus\nRotavirusNorovirusAstrovirus\nCytomegalovirus*AdenovirusHerpes simplex virus\n\n\nProtozoa\n*Cryptosporidium Microsporidium_Cystoisospor*a_CyclosporaGiardia lamblia\nEntamoeba histolytica\n\n\n\n¶ EPEC, EAggEC, EHEC, ETEC may all contribute; routine laboratories and cultures will not differentiate these from E. coli which are normal flora"
  },
  {
    "objectID": "diarrhea.html#small-bowel-vs.-colon",
    "href": "diarrhea.html#small-bowel-vs.-colon",
    "title": "Infectious Diarrheal Diseases",
    "section": "Small Bowel vs. Colon",
    "text": "Small Bowel vs. Colon\n\n\nDiarrhea of small bowel is typically:\n\nWatery\nLarge volume\nAccompanied by abdominal cramping, bloating and gas\n\nDiarrhea of large intestine is typically: - Frequent - Regular - Small volume - Painful - Bloody or mucoid stools (red blood and inflammatory cells seen in stool microscopy)\nCaveat: Patients can have both small and large bowel involvement"
  },
  {
    "objectID": "diarrhea.html#small-bowel-vs.-colon-1",
    "href": "diarrhea.html#small-bowel-vs.-colon-1",
    "title": "Infectious Diarrheal Diseases",
    "section": "Small Bowel vs. Colon",
    "text": "Small Bowel vs. Colon\n\n\n\n\n\n\n\n\n\nPathogen\nSmall bowel\nColon\n\n\n\n\nBacteria\nSalmonellaEscherichia coli¶Clostridium perfringensStaphylococcus aureusAeromonas hydrophilaBacillus cereusVibrio cholerae\nCampylobacterShigellaClostridioides difficileYersiniaVibrio parahaemolyticusEnteroinvasive E. coliPlesiomonas shigelloidesKlebsiella oxytoca (rare)\n\n\nVirus\nRotavirusNorovirusAstrovirus\nCytomegalovirus*AdenovirusHerpes simplex virus\n\n\nProtozoa\n*Cryptosporidium Microsporidium_Cystoisospor*a_CyclosporaGiardia lamblia\nEntamoeba histolytica\n\n\n\n¶ EPEC, EAggEC, EHEC, ETEC may all contribute; routine laboratories and cultures will not differentiate these from E. coli which are normal flora"
  },
  {
    "objectID": "diarrhea.html#inflammatory-signs-with-large-bowel-infection",
    "href": "diarrhea.html#inflammatory-signs-with-large-bowel-infection",
    "title": "Infectious Diarrhea",
    "section": "Inflammatory signs with large-bowel infection",
    "text": "Inflammatory signs with large-bowel infection\n \nThese inflammatory signs associated with large bowel infection (fever, bloody or mucoid stools) suggest invasive bacteria (eg, Salmonella, Shigella, or Campylobacter), enteric viruses (eg, cytomegalovirus [CMV] or adenovirus), Entamoeba histolytica, or a cytotoxic organism such as C. difficile [3].\n\nBloody stools, think: Shiga toxin-producing *E. coli* (STEC) (eg, *E. coli* O157:H7) infection.\n\nOther bacterial causes of visibly bloody diarrhea are *Shigella*, *Campylobacter*, and *Salmonella* species.\nBloody diarrhea can also reflect noninfectious etiologies such as inflammatory bowel disease or ischemic colitis.\nSyndromes that begin with diarrhea but progress to fever and systemic complaints, such as headache and muscle aches, should raise the possibility of :\n\nTyphoidal illness (particularly in travelers from resource-limited settings)\n*Listeria* monocytogenes (particularly if a stiff neck is also present in pregnant patient)"
  },
  {
    "objectID": "diarrhea.html#inflammatory-signs-large-bowel-infection",
    "href": "diarrhea.html#inflammatory-signs-large-bowel-infection",
    "title": "Infectious Diarrheal Diseases",
    "section": "Inflammatory signs: large-bowel infection",
    "text": "Inflammatory signs: large-bowel infection\n\nFever, bloody or mucoid stools suggest invasive bacteria (eg, Salmonella, Shigella, or Campylobacter), enteric viruses (eg, cytomegalovirus [CMV] or adenovirus), Entamoeba histolytica, or C. difficile.\n\nBloody stools, think: Shiga toxin-producing E. coli (STEC) (eg, E. coli O157:H7) infection.\n\nOther bacterial causes of visibly bloody diarrhea are Shigella, Campylobacter, and Salmonella species.\nBloody diarrhea can also reflect noninfectious etiologies such as inflammatory bowel disease or ischemic colitis.\nSyndromes that begin with diarrhea but progress to fever and systemic complaints, such as headache and muscle aches, should raise the possibility of :\n\nTyphoidal illness (particularly in travellers from resource-limited settings)\nListeria monocytogenes (particularly if a stiff neck is also present in pregnant patient)\n\n\n\n\n\n(Riddle et al., 2016)"
  },
  {
    "objectID": "diarrhea.html#medical-hisrtory-exposures",
    "href": "diarrhea.html#medical-hisrtory-exposures",
    "title": "Infectious Diarrhea",
    "section": "Medical Hisrtory: Exposures",
    "text": "Medical Hisrtory: Exposures\n\nFood history, residence, occupational exposure, recent and remote travel, pets, and hobbies, can also provide further diagnostic clues."
  },
  {
    "objectID": "diarrhea.html#medical-history-exposures",
    "href": "diarrhea.html#medical-history-exposures",
    "title": "Infectious Diarrheal Diseases",
    "section": "Medical History: Exposures",
    "text": "Medical History: Exposures\n\n\nFood history\nResidence\nOccupational exposure\nRecent and remote travel\nPets\nHobbies"
  },
  {
    "objectID": "diarrhea.html#food-history",
    "href": "diarrhea.html#food-history",
    "title": "Infectious Diarrheal Diseases",
    "section": "Food history",
    "text": "Food history\n\n\nConsumption of unpasteurized dairy products, raw or undercooked meat or fish, or organic vitamin preparations may suggest certain pathogens.\nThe timing of symptom onset following exposure to the suspected offending food can be an important clue to the diagnosis\n\nWithin six hours – suggests ingestion of a preformed toxin of Staphylococcus aureus or Bacillus cereus, particularly if nausea and vomiting were the initial symptoms\nAt 8 to 16 hours – suggests infection with Clostridium perfringens\nMore than 16 hours – suggests either viral or other bacterial infection (eg, contamination of food with enterotoxigenic or STEC or other pathogens)"
  },
  {
    "objectID": "diarrhea.html#major-foodborne-microbes-by-the-principal-presenting-gastrointestinal-symptom",
    "href": "diarrhea.html#major-foodborne-microbes-by-the-principal-presenting-gastrointestinal-symptom",
    "title": "Infectious Diarrheal Diseases",
    "section": "Major foodborne microbes by the principal presenting gastrointestinal symptom",
    "text": "Major foodborne microbes by the principal presenting gastrointestinal symptom\n\n\n\n\n\n\n\n\n\n\nMajor presenting symptom\nLikely microbes\nIncubation period\nLikely food sources\n\n\n\n\nVomiting\nS. aureus\n1 to 6 hours\nPrepared food, eg, salads, dairy, meat\n\n\nB. cereus\n1 to 6 hours\nRice, meat\n\n\n\nNorwalk-like viruses\n24 to 48 hours\nShellfish, prepared foods, salads, sandwiches, fruit\n\n\n\nWatery diarrhea\nC. perfringens\n8 to 16 hours\nMeat, poultry, gravy\n\n\nEnterotoxigenic E. coli\n1 to 3 days\nFecally contaminated food or water\n\n\n\nEnteric viruses\n10 to 72 hours\nFecally contaminated food or water\n\n\n\nC. parvum\n2 to 28 days\nVegetables, fruit, unpasteurized milk, water\n\n\n\nC. cayetanensis\n1 to 11 days\nImported berries, basil\n\n\n\nInflammatory diarrhea\nCampylobacter spp\n2 to 5 days\nPoultry, unpasteurized milk, water\n\n\nNontyphoidal Salmonella\n1 to 3 days\nEggs, poultry, meat, unpasteurized milk or juice, fresh produce\n\n\n\nShiga toxin-producing E. coli\n1 to 8 days\nGround beef, unpasteurized milk and juice, raw vegetables, water\n\n\n\nShigella spp\n1 to 3 days\nFecal contamination of food and water\n\n\n\nV. parahemolyticus\n2 to 48 hours\nRaw shellfish\n\n\n\n\nIncubation period and likely food sources are shown for each.\nModified from Centers for Disease Control and Prevention. Diagnosis and management of food borne illness, a primer for physicians. MMWR Recomm Rep April 16, 2004 / 53(RR04);1-33"
  },
  {
    "objectID": "diarrhea.html#other-exposures",
    "href": "diarrhea.html#other-exposures",
    "title": "Infectious Diarrheal Diseases",
    "section": "Other exposures",
    "text": "Other exposures\n\n\nExposure to animals (poultry, turtles, petting zoos) has been associated with Salmonella infection.\nTravel to a resource-limited setting increases the risk of bacterial diarrhea and also informs the risk of certain parasitic infections\nOccupation in daycare centres has been associated with:\n\ninfections with Shigella, Cryptosporidium, and Giardia.\nRotavirus is a potential consideration, but decreased with vaccination"
  },
  {
    "objectID": "diarrhea.html#additional-medical-history",
    "href": "diarrhea.html#additional-medical-history",
    "title": "Infectious Diarrheal Diseases",
    "section": "Additional Medical history",
    "text": "Additional Medical history\n\n\nRecent antibiotic use (as a clue to the presence of C. difficile infection)\nOther medications (such as proton pump inhibitors, which can increase the risk of infectious diarrhea)\nPredisposing conditions:\n\nImmunocompromised host or the possibility of nosocomial infection\nMedical history informing the likelihood of various pathogens\nPregnancy increases the risk of listeriosis following consumption of contaminated meat products or unpasteurized dairy products approximately 20-fold\nCirrhosis has been associated with Vibrio infection\nHemochromatosis has been associated with Yersinia infection"
  },
  {
    "objectID": "diarrhea.html#physical-exam",
    "href": "diarrhea.html#physical-exam",
    "title": "Infectious Diarrhea",
    "section": "Physical exam",
    "text": "Physical exam\nThe examination focuses on evaluating volume status and identifying complications. - Volume depletion can be suggested by - dry mucous membranes, - diminished skin turgor, - postural or frank reductions in blood pressure - and altered sensorium - These signs can be mild or absent with early hypovolemia - The abdominal examination should evaluate for findings that can suggest ileus or peritonitis, including abdominal distension, pain with gentle percussion, abdominal rigidity, or rebound tenderness - Laboratory exam: - Laboratory tests are not routinely warranted for most patients with acute diarrhea. - If substantial volume depletion is present (suggested by signs or symptoms such as dark and concentrated urine), a basic metabolic panel should be performed to screen for hypokalemia or renal dysfunction - The complete blood count does not reliably distinguish bacterial etiologies of diarrhea from others but may be helpful in suggesting severe disease or potential complications - A low platelet count may prompt concern for the development of the hemolytic-uremic syndrome - Leukemoid reaction is consistent with the diagnosis of C. difficile infection. - Blood cultures should be obtained in patients with high fevers or who appear systemically ill - Stool testing for bacterial pathogens\nReferences\n\n\n\n\n\n\n\nDryden MS, Gabb RJ, Wright SK. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 1996;22:1019–25. https://doi.org/10.1093/clinids/22.6.1019.\n\n\nFang FC, Patel R. 2017 Infectious Diseases Society of America Infectious Diarrhea Guidelines: A View From the Clinical Laboratory. Clinical Infectious Diseases 2017;65:1974–6. https://doi.org/10.1093/cid/cix730.\n\n\nGBD 2016 Diarrhoeal Disease Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet Infectious Diseases 2018;18:1211–28. https://doi.org/10.1016/S1473-3099(18)30362-1.\n\n\nRiddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults. The American Journal of Gastroenterology 2016;111:602–22. https://doi.org/10.1038/ajg.2016.126."
  },
  {
    "objectID": "diarrhea.html#physical-exam-1",
    "href": "diarrhea.html#physical-exam-1",
    "title": "Infectious Diarrheal Diseases",
    "section": "Physical exam-1",
    "text": "Physical exam-1\n\n\nExam focus- volume status and identifying complications\n\nVolume depletion can be suggested by:\n\ndry mucous membranes\ndiminished skin turgor\n\npostural or frank reductions in blood pressure\naltered sensorium\n\n\nThese signs can be mild or absent with early hypovolemia"
  },
  {
    "objectID": "diarrhea.html#physical-exam-2",
    "href": "diarrhea.html#physical-exam-2",
    "title": "Infectious Diarrheal Diseases",
    "section": "Physical exam-2",
    "text": "Physical exam-2\n\nAbdominal examination should focus on signs that suggest ileus or peritonitis\n\nAbdominal distension\nPain with gentle percussion\nAbdominal rigidity, or rebound tenderness\n\n{width=“600” center}"
  },
  {
    "objectID": "diarrhea.html#laboratory-exam",
    "href": "diarrhea.html#laboratory-exam",
    "title": "Infectious Diarrheal Diseases",
    "section": "Laboratory exam",
    "text": "Laboratory exam\n\nLaboratory tests are not routinely warranted for most patients with acute diarrhea\nIf substantial volume depletion is present (suggested by signs or symptoms such as dark and concentrated urine), a basic metabolic panel should be performed to screen for hypokalemia or renal dysfunction\nThe complete blood count does not reliably distinguish bacterial etiologies of diarrhea from others but may be helpful in suggesting severe disease or potential complications\n\nA low platelet count may prompt concern for the development of the hemolytic-uremic syndrome\nLeukemoid reaction is consistent with the diagnosis of C. difficile infection.\n\nBlood cultures should be obtained in patients with high fevers or who appear systemically ill"
  },
  {
    "objectID": "diarrhea.html#stool-cultures",
    "href": "diarrhea.html#stool-cultures",
    "title": "Infectious Diarrheal Diseases",
    "section": "Stool cultures",
    "text": "Stool cultures\n\n\nThe optimal specimen for culture is a diarrheal stool specimen (conforms to container)o, which should be inoculated onto culture plates as quickly as possible.\nRoutine stool culture will identify Salmonella, Campylobacter, and Shigella\nE. coli O157:H7 can be isolated on sorbitol-MacConkey plates or identified with antigen testing or polymerase chain reaction of stool\nA stool culture that is positive for one of these pathogens in a patient with acute diarrheal symptoms can be interpreted as a true positive.\nIf a stool specimen cannot be obtained promptly, a rectal swab culture can be obtained to accelerate the diagnosis although some data suggest decreased sensitivity in adults\nMay need to specify bacteria of interest\n\nCampylobacter\nAeromonas, Yersina\nVibrio-requires selective media\n\nBacterial pathogens are generally excreted continuously, in contrast to ova and parasites, which are often shed intermittently.\nThus, a negative culture is usually not a false negative, and repeat specimens are rarely required."
  },
  {
    "objectID": "diarrhea.html#when-to-consider-stool-cultures",
    "href": "diarrhea.html#when-to-consider-stool-cultures",
    "title": "Infectious Diarrheal Diseases",
    "section": "When to consider stool cultures",
    "text": "When to consider stool cultures\n\n\n\nSevere illness\n\nProfuse watery diarrhea with signs of hypovolemia\nPassage of > 6 unformed stools per 24 hours\nSevere abdominal pain\nneed for hospitalization\n\nOther signs of symptoms concerning for inflammatory diarrhea\n\nBloody diarrhea\nPassage of many small stools containing blood and mucus\nTemperature >38.5°\n\nHigh-risk host features\n\nAge ≥ 70 years\nComorbidities such as cardiac disease (exacerbated by hypovolemia or complicating fluid replacement)\nImmunocompromised condition (including advanced HIV)\nInflammatory bowel disease\nPregnancy\nSymptoms persisting more than 1 week\n\nPublic health issue\n\n\nGoal: Identify a potential bacterial pathogen that would inform the potential for complications and treatment decisions"
  },
  {
    "objectID": "diarrhea.html#when-to-consider-stool-cultures-.smaller",
    "href": "diarrhea.html#when-to-consider-stool-cultures-.smaller",
    "title": "Infectious Diarrheal Diseases",
    "section": "When to consider stool cultures {.smaller}",
    "text": "When to consider stool cultures {.smaller}\n\n\n\nSevere illness\n\nProfuse watery diarrhea with signs of hypovolemia\nPassage of > 6 unformed stools per 24 hours\nSevere abdominal pain\nneed for hospitalization\n\nOther signs of symptoms concerning for inflammatory diarrhea\n\nBloody diarrhea\nPassage of many small stools containing blood and mucus\nTemperature >38.5°\n\nHigh-risk host features\n\nAge ≥ 70 years\nComorbidities such as cardiac disease (exacerbated by hypovolemia or complicating fluid replacement)\nImmunocompromised condition (including advanced HIV)\nInflammatory bowel disease\nPregnancy\nSymptoms persisting more than 1 week\n\nPublic health issue\n\n\nGoal: Identify a potential bacterial pathogen that would inform the potential for complications and treatment decisions"
  },
  {
    "objectID": "diarrhea.html#when-are-tool-cultures-considered",
    "href": "diarrhea.html#when-are-tool-cultures-considered",
    "title": "Infectious Diarrheal Diseases",
    "section": "When are tool cultures considered",
    "text": "When are tool cultures considered\n\n\n\nSevere illness\n\nProfuse watery diarrhea with signs of hypovolemia\nPassage of > 6 unformed stools per 24 hours\nSevere abdominal pain\nNeed for hospitalization\n\nOther signs of symptoms concerning for inflammatory diarrhea\n\nBloody diarrhea\nPassage of many small stools containing blood and mucus\nTemperature >38.5°\n\nHigh-risk host features\n\nAge ≥ 70 years\nComorbidities such as cardiac disease (exacerbated by hypovolemia or complicating fluid replacement)\nImmunocompromised condition (including advanced HIV)\nInflammatory bowel disease\nPregnancy\nSymptoms persisting more than 1 week\n\nPublic health issue *e\n\n\nGoal: Identify a potential bacterial pathogen that would inform the potential for complications and treatment decisions"
  },
  {
    "objectID": "diarrhea.html#when-are-stool-cultures-considered",
    "href": "diarrhea.html#when-are-stool-cultures-considered",
    "title": "Infectious Diarrheal Diseases",
    "section": "When are stool cultures considered?",
    "text": "When are stool cultures considered?\n\n\n\nSevere illness\n\nProfuse watery diarrhea with signs of hypovolemia\nPassage of &gt; 6 unformed stools per 24 hours\nSevere abdominal pain\nNeed for hospitalization\n\nOther signs of symptoms concerning for inflammatory diarrhea\n\nBloody diarrhea\nPassage of many small stools containing blood and mucus\nTemperature &gt;38.5°\n\nHigh-risk host features\n\nAge ≥ 70 years\nComorbidities such as cardiac disease (exacerbated by hypovolemia or complicating fluid replacement)\nImmunocompromised condition (including advanced HIV)\nInflammatory bowel disease\nPregnancy\nSymptoms persisting more than 1 week\n\nSuspected public health issue\n\n\nGoal: Identify a potential bacterial pathogen that would inform the potential for complications and treatment decisions"
  },
  {
    "objectID": "diarrhea.html#stool-testing-molecular-methods",
    "href": "diarrhea.html#stool-testing-molecular-methods",
    "title": "Infectious Diarrheal Diseases",
    "section": "Stool testing: molecular methods",
    "text": "Stool testing: molecular methods\n\nMultipathogen molecular panels — Some laboratories have access to multiplex stool tests, with which molecular tests for a panel of many different pathogens (bacterial, viral, and parasitic) can be performed simultaneously on diarrheal stool samples and, in some cases, rectal swab"
  },
  {
    "objectID": "diarrhea.html#red-flag-symptoms-requiring-urgent-investigation",
    "href": "diarrhea.html#red-flag-symptoms-requiring-urgent-investigation",
    "title": "Infectious Diarrheal Diseases",
    "section": "Red flag symptoms requiring urgent investigation",
    "text": "Red flag symptoms requiring urgent investigation\n\n\nPeristent stool > 1 week\nFever\nBloody diarrhea\nSevere abdominal pain\nSigns and symptoms of dehydration (tachycardia, hypotension, confusion, decreased urine output)\nWeight loss\nRecent hospital stay of antibiotic exposure\nPregnant\nOver the age of 65 years\nDiabetic, living with HIV, or immunocompromised"
  },
  {
    "objectID": "diarrhea.html#norovirus-winter-vomiting-virus",
    "href": "diarrhea.html#norovirus-winter-vomiting-virus",
    "title": "Infectious Diarrheal Diseases",
    "section": "Norovirus “winter vomiting virus”",
    "text": "Norovirus “winter vomiting virus”\n\n\n\n(Ahmed et al., 2014)"
  },
  {
    "objectID": "diarrhea.html#norovirus",
    "href": "diarrhea.html#norovirus",
    "title": "Infectious Diarrheal Diseases",
    "section": "Norovirus",
    "text": "Norovirus\n\n\nEpidemiology\n\nNonenveloped RNA virus from Caliciviradae family\nMost common cause of gastroenteritis worldwide\nAlthough antibody prevalence rises through childhood, re-infection is common as their is no lasting immunity due to re-infection with diversity of strains\n\nTransmission\n\nSpread by fecal-oral route from person to person, aerosol in vomitus, contaminated food and water, fomite on surfaces (resists killing by alcohol or chlorine, temperatures up to 60°C)\nOutbreaks are common"
  },
  {
    "objectID": "diarrhea.html#extraintestinal-manifestations",
    "href": "diarrhea.html#extraintestinal-manifestations",
    "title": "Infectious Diarrheal Diseases",
    "section": "Extraintestinal manifestations",
    "text": "Extraintestinal manifestations\n\n\n\nSymptoms:\n\nPersistent fever\nBloody diarrhea\nSevere abdominal pain\nSymptoms of volume depletion (eg, dark or scant urine, symptoms of orthostasis)\nHistory of inflammatory bowel disease\nHospitalization should be considered:\nHistory of immunosuppression (e.g., treatment for malignancy, transplantation, HIV\nSignificant cardiovascular diseases"
  },
  {
    "objectID": "diarrhea.html#norovirus-1",
    "href": "diarrhea.html#norovirus-1",
    "title": "Infectious Diarrheal Diseases",
    "section": "Norovirus",
    "text": "Norovirus\n\n\nClinical manifestations:\n\nVomiting\nWatery diarrhea, non-bloody and non-bilious, 4-8 stools/ 24 hours period\nFever in 50% of cases\nMalaise, headache\nAbdominal pain\nPatients at risk of dehydration\nWhite blood cell count elevated or normal, lymphopenia common\nShort duration of illness (48-72 hours) with complete recovery\n\nDiagnosis:\n\nDiagnosed clinically although antigen detection (enzyme immunoassay) or PCR may be used in outbreak settings.\n\nTreatment:\n\nSupportive care (hydration)"
  },
  {
    "objectID": "diarrhea.html#rotavirus",
    "href": "diarrhea.html#rotavirus",
    "title": "Infectious Diarrheal Diseases",
    "section": "Rotavirus",
    "text": "Rotavirus\n\nMean duration of symptoms for 3-8 days\nOccurs in children 6 months-2 years\nOccasionally causes diarrhea in elderly\nVomiting less of a prominent feature vs. norovirus\n\n\nImage: Centers for Disease Control"
  },
  {
    "objectID": "diarrhea.html#enterotoxigenic-e.-coli-etec",
    "href": "diarrhea.html#enterotoxigenic-e.-coli-etec",
    "title": "Infectious Diarrheal Diseases",
    "section": "Enterotoxigenic E. coli (ETEC)",
    "text": "Enterotoxigenic E. coli (ETEC)"
  },
  {
    "objectID": "diarrhea.html#enterotoxigenic-escherichia-coli-etec",
    "href": "diarrhea.html#enterotoxigenic-escherichia-coli-etec",
    "title": "Infectious Diarrheal Diseases",
    "section": "Enterotoxigenic Escherichia coli (ETEC)",
    "text": "Enterotoxigenic Escherichia coli (ETEC)\n\n\nCause of dehydrating diarrhea , especially in developing world (&lt; 2 years age) due to ability to survive in water and production of heat-stabile and heat-labile toxins\nCauses watery diarrhea in returning travellers with nausea but no vomiting and symptoms lasting as long as 5 days"
  },
  {
    "objectID": "diarrhea.html#enteropathogenic-e.-coli-epec",
    "href": "diarrhea.html#enteropathogenic-e.-coli-epec",
    "title": "Infectious Diarrheal Diseases",
    "section": "Enteropathogenic E. coli (EPEC)",
    "text": "Enteropathogenic E. coli (EPEC)\n\n\nDiarrhea common in children &lt; 6 months in developing world\nSporadic outbreaks in adults\nSevere diarrhea that can result in dehydration and malnutrition"
  },
  {
    "objectID": "diarrhea.html#entero-hemorrhagic-e-coli-ehec-of-shiga-toxin-producing-e.-coli-stec",
    "href": "diarrhea.html#entero-hemorrhagic-e-coli-ehec-of-shiga-toxin-producing-e.-coli-stec",
    "title": "Infectious Diarrheal Diseases",
    "section": "Entero-hemorrhagic E coli (EHEC, of Shiga toxin-producing E. coli (STEC)",
    "text": "Entero-hemorrhagic E coli (EHEC, of Shiga toxin-producing E. coli (STEC)"
  },
  {
    "objectID": "diarrhea.html#entero-hemorrhagic-e-coli-ehec-or-shiga-toxin-producing-e.-coli-stec",
    "href": "diarrhea.html#entero-hemorrhagic-e-coli-ehec-or-shiga-toxin-producing-e.-coli-stec",
    "title": "Infectious Diarrheal Diseases",
    "section": "Entero-hemorrhagic E coli (EHEC)  or Shiga toxin-producing E. coli (STEC)",
    "text": "Entero-hemorrhagic E coli (EHEC)  or Shiga toxin-producing E. coli (STEC)\n\nIncubation of 1-4 days\nMain serotypes E. coli O157:H7 or E. coli O101:h4 (STEC)\nOften cause bloody diarrhea, abdominal tenderness with lack of fever\nOccasional cause of pseudomembraneous colitis (when negative for C. difficile)\nIncreased White blood cell count\nAssociated with outbreaks (contaminated food)\nCan cause hemolytic uremia syndrome (5-10 days after diarrhea) 6-9% of EHEC infections affecting mostly children < 10 years:\n\nRenal failure\nThrombocytopenia\nThrombotic microangiopathic anemia (↓ PLT count, haptoglobin, RBC, ↑LDH, SeCr)\n\nNeurologic symptoms-motor deficits and seizure)"
  },
  {
    "objectID": "diarrhea.html#italy-e.-coli-0157h7",
    "href": "diarrhea.html#italy-e.-coli-0157h7",
    "title": "Infectious Diarrheal Diseases",
    "section": "Italy: E. coli 0157:H7",
    "text": "Italy: E. coli 0157:H7"
  },
  {
    "objectID": "diarrhea.html#schistocytes-seen-in-peripheral-blood-with-hus",
    "href": "diarrhea.html#schistocytes-seen-in-peripheral-blood-with-hus",
    "title": "Infectious Diarrheal Diseases",
    "section": "Schistocytes seen in peripheral blood with HUS",
    "text": "Schistocytes seen in peripheral blood with HUS"
  },
  {
    "objectID": "diarrhea.html#hus-long-term-sequelae",
    "href": "diarrhea.html#hus-long-term-sequelae",
    "title": "Infectious Diarrheal Diseases",
    "section": "HUS long-term sequelae",
    "text": "HUS long-term sequelae\n\n\nRenal failure and hypertension (39%)"
  },
  {
    "objectID": "diarrhea.html#how-can-e.-coli-o157-infection-be-detected",
    "href": "diarrhea.html#how-can-e.-coli-o157-infection-be-detected",
    "title": "Infectious Diarrheal Diseases",
    "section": "How can E. coli O157 infection be detected?",
    "text": "How can E. coli O157 infection be detected?\n\n\nCulture on sorbitol MacConkey (SMAC) agar with first 6 days of bloody diarrhea\n\nE. coli O157 cannot ferment lactose, but can ferment sorbitol\n\nToxin detection (Shiga toxin, EIA in stool)"
  },
  {
    "objectID": "diarrhea.html#why-is-it-important-to-identify-e.-coli-0157-ehec",
    "href": "diarrhea.html#why-is-it-important-to-identify-e.-coli-0157-ehec",
    "title": "Infectious Diarrheal Diseases",
    "section": "Why is it important to identify E. coli 0157 (EHEC)?",
    "text": "Why is it important to identify E. coli 0157 (EHEC)?\n\n\nTracing an outbreak (i.e. contaminated produce)\nAntibiotic therapy increases the risk of HUS in EHEC by 25% and should be avoided, especially in young children\nTreatment with supportive measures and avoidance of anti-motility agents (e.g., loperamide) to reduce the risk of complications"
  },
  {
    "objectID": "diarrhea.html#campylobacter",
    "href": "diarrhea.html#campylobacter",
    "title": "Infectious Diarrheal Diseases",
    "section": "Campylobacter",
    "text": "Campylobacter\n\n\nGram-negative that belongs to the Enterobacterales (previously known as a Vibrio-type organism associated with abortion in cattle and sheep)\nSeen worldwide and a leading cause of gastroenteritis, including in the Arctic and temperate areas\nCampylobacter jejuni most common species"
  },
  {
    "objectID": "diarrhea.html#salmonella",
    "href": "diarrhea.html#salmonella",
    "title": "Infectious Diarrheal Diseases",
    "section": "Salmonella",
    "text": "Salmonella\n\nMotile Gram-negative bacteria that belong to the Enterobacterales\nCan cause:\n\nGastroenteritis with non-typhoidal Salmonella spp.\nEnteric fever (Salmonella typhi and Salmonella paratyphi)\nBacteremia and endovascular infections\nOsteomyelitis and deep-seated metastatic abscess\nAsymptomatic carriage"
  },
  {
    "objectID": "diarrhea.html#enteric-fever-or-typhoid-salmonella-enterica-serotype-tyhphi",
    "href": "diarrhea.html#enteric-fever-or-typhoid-salmonella-enterica-serotype-tyhphi",
    "title": "Infectious Diarrheal Diseases",
    "section": "Enteric fever or typhoid (Salmonella enterica serotype tyhphi)",
    "text": "Enteric fever or typhoid (Salmonella enterica serotype tyhphi)"
  },
  {
    "objectID": "diarrhea.html#other-e.-coli--enteroinvasive-eiec-and-enteroaggregative-eaggec",
    "href": "diarrhea.html#other-e.-coli--enteroinvasive-eiec-and-enteroaggregative-eaggec",
    "title": "Infectious Diarrheal Diseases",
    "section": "Other E. coli- Enteroinvasive (EIEC) and Enteroaggregative (EaggEC)",
    "text": "Other E. coli- Enteroinvasive (EIEC) and Enteroaggregative (EaggEC)\n\n\nEIEC relatively rare, closely related to Shigella\n\nOften watery diarrhea- rarely progresses to bloody diarrhea\n\nEaggEC\n\nAffects the immunocompromised\nCause of persistent diarrhea in patients with HIV\nAffects young children more frequently\nCan often be eradicated with antibiotics"
  },
  {
    "objectID": "diarrhea.html#enteric-fever-or-typhoid-salmonella-enterica-serotype-typhi",
    "href": "diarrhea.html#enteric-fever-or-typhoid-salmonella-enterica-serotype-typhi",
    "title": "Infectious Diarrheal Diseases",
    "section": "Enteric fever or typhoid (Salmonella enterica serotype typhi)",
    "text": "Enteric fever or typhoid (Salmonella enterica serotype typhi)\n\n\nHumans the only know reservoir for infection\nTransmission through fecal-oral route, through direct contact with infected individual or indirect contact through food or water\n\nCommon in impoverished areas of the world\nHighest rates in South-East Asia and East Africa\n\nAfflicts young children and Elderly\nOften seen in returning travellers from Endemic areas- risk of antibiotic resistance\n1-6% have chronic carriage with shedding in urine and stool for &gt; 12 months after infection (esp. biliary tree infection with stones)"
  },
  {
    "objectID": "diarrhea.html#clostridiodes-clostridium-difficile",
    "href": "diarrhea.html#clostridiodes-clostridium-difficile",
    "title": "Infectious Diarrheal Diseases",
    "section": "Clostridiodes (Clostridium) difficile",
    "text": "Clostridiodes (Clostridium) difficile"
  },
  {
    "objectID": "diarrhea.html#campylobacter-transmission",
    "href": "diarrhea.html#campylobacter-transmission",
    "title": "Infectious Diarrheal Diseases",
    "section": "Campylobacter transmission",
    "text": "Campylobacter transmission\n\n\nCommon commensal in GI tract of wild and domestic animals, poultry and birds\n\nFood handlers: good hand hygiene essential; meat should be cooked to high temperatures (82°C, 180°F).\nDon’t drink unpasteurized milk\nInfection can occur from eating undercooked meat\n\nCampylobacter survive in freshwater (including at temps below (15°C) → infection from swimming or drinking contaminated water\nDirect transmission from infected animals, pets, carcasses- handwashing should be encouraged especially for vulnerable adults or children visiting farms or petting zoos\nPerson-to-person transmission (nursery staff working with infected children)\nSexual transmission\nIncreased infection risk in patients with increased gastric acidity (achlorhydria or proton pump inhibitor use)"
  },
  {
    "objectID": "diarrhea.html#clinical-factures-of-campylobacter-infection",
    "href": "diarrhea.html#clinical-factures-of-campylobacter-infection",
    "title": "Infectious Diarrheal Diseases",
    "section": "Clinical factures of campylobacter infection",
    "text": "Clinical factures of campylobacter infection\n\n\nMean incubation 3 days (range 1-7)\nCampylobacter can affect either large or small bowel, hence causes both watery and bloody diarrhea\nClassic prodrome: Fevers, rigours, dizziness in 1/3 of patients prior to GI symptoms → increased severity of disease\nAbdominal pain:\n\nAbrupt, sever, cramping, colicky, periumbilical- not always accompanied by diarrhea\nRadiates"
  },
  {
    "objectID": "diarrhea.html#clinical-features-of-campylobacter-infection",
    "href": "diarrhea.html#clinical-features-of-campylobacter-infection",
    "title": "Infectious Diarrheal Diseases",
    "section": "Clinical features of Campylobacter infection",
    "text": "Clinical features of Campylobacter infection\n\n\n\nMean incubation 3 days (range 1-7)\nCampylobacter can affect either large or small bowel, hence causes both watery and bloody diarrhea\nClassic prodrome: Fevers, rigours, dizziness in 1/3 of patients prior to GI symptoms → increased severity of disease\nAbdominal pain:\n\nAbrupt, sever, cramping, colicky, periumbilical- not always accompanied by diarrhea\nRadiates to right iliac fossa in time, mimicking appendicitis and may persist after diarrhea settles\nNausea and vomiting (15-25% of patients)\nBacteremia (0.1-1%), especially immunocompromised, hypogammaglobulinemic"
  },
  {
    "objectID": "diarrhea.html#campylobacter-complications",
    "href": "diarrhea.html#campylobacter-complications",
    "title": "Infectious Diarrheal Diseases",
    "section": "Campylobacter complications",
    "text": "Campylobacter complications\n\n\nGuillian-Barré disease\n\nAcute, immune-related polyneuropathy that occurs 1-2 weeks after infections\nLinked to Campylobacter infection in 3-40% of cases, alterative variate Miller-Fischer\n\n100-fold higher incidence vs. population following C. jejuni infection\nMechanism: Antibody formation that cross-reacts with GM1 ganglioside present in peripheral nerve myelin\n\n\nReactive arthritis\n\nSeen in 2.6% of patients, not related to severity of illness\nLinked to HLAB27\nOnset 1-2 weeks after infection, affecting joints, wrist, knees, ankles\nMay last for several weeks to months\nTypically resolves, treated with non-steroidal anti-inflammatory agents (NSAIDS)"
  },
  {
    "objectID": "diarrhea.html#campylobacter-diagnosis",
    "href": "diarrhea.html#campylobacter-diagnosis",
    "title": "Infectious Diarrheal Diseases",
    "section": "Campylobacter diagnosis",
    "text": "Campylobacter diagnosis\n\nStool culture Gram stain"
  },
  {
    "objectID": "diarrhea.html#general-etiology",
    "href": "diarrhea.html#general-etiology",
    "title": "Infectious Diarrheal Diseases",
    "section": "General Etiology",
    "text": "General Etiology\n \n\nMost cases of acute diarrhea are due to infections and are self-limited\nMost cases of acute infectious diarrhea are viral, as indicated by the observation that stool cultures are positive in only 1.5 to 5.6 % of cases\nThe major causes of acute infectious diarrhea include:\n\nViruses (norovirus, rotavirus, adenoviruses, astrovirus, and others)\nBacteria (Salmonella, Campylobacter, Shigella, enterotoxigenic Escherichia coli, Clostridioides difficile, and others)\nProtozoa (Cryptosporidium, Giardia, Cyclospora, Entamoeba, and others)\n\n\n\n\n(Dryden et al., 1996)"
  },
  {
    "objectID": "diarrhea.html#red-flag-symptoms--urgent-investigation",
    "href": "diarrhea.html#red-flag-symptoms--urgent-investigation",
    "title": "Infectious Diarrheal Diseases",
    "section": "Red flag symptoms- urgent investigation",
    "text": "Red flag symptoms- urgent investigation\n\n\nPeristent stool &gt; 1 week\nFever\nBloody diarrhea\nSevere abdominal pain\nSigns and symptoms of dehydration (tachycardia, hypotension, confusion, decreased urine output)\nWeight loss\nRecent hospital stay or antibiotic exposure\nPregnant\nOver the age of 65 years\nDiabetic, living with HIV, or immunocompromised"
  },
  {
    "objectID": "diarrhea.html#entero-hemorrhagic-e.-coli-ehec-or-shiga-toxin-producing-e.-coli-stec",
    "href": "diarrhea.html#entero-hemorrhagic-e.-coli-ehec-or-shiga-toxin-producing-e.-coli-stec",
    "title": "Infectious Diarrheal Diseases",
    "section": "Entero-hemorrhagic E. coli (EHEC)  or Shiga toxin-producing E. coli (STEC)",
    "text": "Entero-hemorrhagic E. coli (EHEC)  or Shiga toxin-producing E. coli (STEC)\n\nIncubation of 1-4 days\nMain serotypes E. coli O157:H7 or E. coli O101:h4 (STEC)\nOften cause bloody diarrhea, abdominal tenderness with lack of fever\nOccasional cause of pseudomembranous colitis (when negative for C. difficile)\nIncreased white blood cell count\nAssociated with outbreaks (contaminated food)\nCan cause hemolytic uremia syndrome (5-10 days after diarrhea) 6-9% of EHEC infections affecting mostly children &lt; 10 years:\n\nRenal failure\nThrombocytopenia\nThrombotic microangiopathic anemia (↓ PLT count, haptoglobin, RBC, ↑LDH, SeCr)\n\nNeurologic symptoms-motor deficits and seizure (4%)"
  },
  {
    "objectID": "diarrhea.html#campylobacter-infections-treatment",
    "href": "diarrhea.html#campylobacter-infections-treatment",
    "title": "Infectious Diarrheal Diseases",
    "section": "Campylobacter infections: Treatment",
    "text": "Campylobacter infections: Treatment\n&lt;br&gt;\n\nGenerally self-limiting, antimicrobial resistance a problem (e.g., fluoroquinolone resistance in SE Asia)\nAntibiotic treatment has been shown to reduce symptoms duration by 1 day, but is indicated when patient is:\n\nImmunocompromised or pregnant\nHas severe disease with fever, bloody diarrhea, symptoms &gt; 1 week, relapsing symptoms, or extraintestinal disease\n\nGeneral approach: ciprofloxacin/levofloxacin or azithromycin x 3 days or until sings and symptoms have improved\n\n7-14 days therapy recommended in immunocompromised\n\nIn severe infections with bacteremia or patients unable to tolerate oral medication: carbapenem + aminoglycoside"
  },
  {
    "objectID": "diarrhea.html#salmonella-epidemiology",
    "href": "diarrhea.html#salmonella-epidemiology",
    "title": "Infectious Diarrheal Diseases",
    "section": "Salmonella epidemiology",
    "text": "Salmonella epidemiology\n\nNon-typhoidal Salmonella causes inflammatory diarrhea worldwide\nSalmonella enteritidis and Salmonella typhimurium are the most common causes of diarrhea\nHighest incidence: Asia (4 per 100 cases); second to norovirus in other developed countries\nSeasonal variation with peaks of infection in summer and autumn"
  },
  {
    "objectID": "diarrhea.html#salmonella-transmission",
    "href": "diarrhea.html#salmonella-transmission",
    "title": "Infectious Diarrheal Diseases",
    "section": "Salmonella transmission",
    "text": "Salmonella transmission\n\n\nFeco-oral route; ingestion of poultry, eggs, and meat products including fresh produce\nTransovarial transmission can occur from infected henst to intreact egg shells, subsequently resulting in infection\nContaminated infant milk\nContact with animals colonized with Salmonella spp. (snakes, iguana, lizards, frogs, turtles in particular) also mice, rats , hamsters, cats, dogs, chickens, ducklings\nPetting farms and zoos\nTravel oversees and poor food and water hygiene"
  },
  {
    "objectID": "diarrhea.html#clinical-features",
    "href": "diarrhea.html#clinical-features",
    "title": "Infectious Diarrheal Diseases",
    "section": "Clinical features",
    "text": "Clinical features\n\n\nIncubation period of 8-72 hours following ingestion of contained water/food (inoculum dependent\nSeverity of symptoms related to bacterial dose- mild symptoms and asymptomatic carriage can occur\nDiarrhea with abdominal pain that resolves in 4-7 days, nausa, voming and fever generally resolve in &lt; 72 hours\nBloody stools in children\nLess than 5% of non-typhoidal Salmonella develop bactermeia\n\nHowever, when bacteremia develops: mycotic aneurysms, abscess, osteomyelitis, infective endocarditis, endovascular infection\n\nPatients with achlorhydria, inflammatory bowel disease, sickly cell disease are susceptible to more severe infection"
  },
  {
    "objectID": "diarrhea.html#antibiotic-treatment",
    "href": "diarrhea.html#antibiotic-treatment",
    "title": "Infectious Diarrheal Diseases",
    "section": "Antibiotic treatment",
    "text": "Antibiotic treatment\n\n\nGuided by antimicrobial sensitivity when possible\n\nPreferred agents: fluoroquinolones (ciprofloxacin, levofloxacin) but resistance increasing\nAlternatives: ceftriaxone, azithromycin, trimethoprim-sulfamethoxazone\n\nTreatment duration:\n\n3-7 days with severe GI disease but no bacteremia\n3-14 days if at risk for endovascular infections or joint complications; or older patient\n\nImmunosuppressed patients have problems clearing Salmonella because it persists in reticuloendothelial cell system (RES)- prolonged treatment is required and patients are at higher risk for metastatic infections\n\n14 days minimum to prevent infection relapsing or persisting\nPatients with HIV with gastroenteritis may require 2-6 weeks of therapy"
  },
  {
    "objectID": "diarrhea.html#asymptomatic-carriage",
    "href": "diarrhea.html#asymptomatic-carriage",
    "title": "Infectious Diarrheal Diseases",
    "section": "Asymptomatic carriage",
    "text": "Asymptomatic carriage\n\nCompared to other serotypes, Salmonella typhimurium is cleared quickly (less carriage)\nFollowing symptomatic infection, excretion can continue fora prolonged period-5 weeks\nShedding can be intermittent, hence several cultures are required to detect carriage\nPrevious short course antibiotic therapy does not reduce carriage, and may prolong shedding\nChronic carrier states\n\nContinued shedding for over 1 year (0.6-2%)\n\nMore common in women, older adults, young children, biliary tract abnormalities (e.g., gallstones)- may require cholecystectomy\nCan attempt prolonged antibiotic therapy for clearance:\n\nQuinolones 4-6 weeks, or amoxicillin or ampicillin 6 weeks or trimethoprim-sulfamethoxazole for 3 months\nFollow-up cultures after 6 months performed to confirm eradication\n\n\nLocal health policies have specific rules about return to work (food handlers, healthcare workers)"
  },
  {
    "objectID": "diarrhea.html#clostridioides-clostridium-difficile",
    "href": "diarrhea.html#clostridioides-clostridium-difficile",
    "title": "Infectious Diarrheal Diseases",
    "section": "Clostridioides (Clostridium) difficile",
    "text": "Clostridioides (Clostridium) difficile"
  },
  {
    "objectID": "diarrhea.html#clinical-features-of-enteric-fever",
    "href": "diarrhea.html#clinical-features-of-enteric-fever",
    "title": "Infectious Diarrheal Diseases",
    "section": "Clinical features of enteric fever",
    "text": "Clinical features of enteric fever\n\nStepwise over a series of weeks:\n\nWeek 1: Fevers > 40°C with bacteremeia, chills, rigours, bradycardia with pulse temperature association (see FUO lecture)\nWeek 2: Abdominal pain, “rose spots”\n\n\n\n\nSpec et al. Comprehensive Review of Infectious Diseases"
  },
  {
    "objectID": "diarrhea.html#shigella",
    "href": "diarrhea.html#shigella",
    "title": "Infectious Diarrheal Diseases",
    "section": "Shigella",
    "text": "Shigella\n\nNonmotile Gram-negative facultative anaerobic bacteria belonging to Enterobacterales\n\nS. dysenteriae (Serogroup A)\nS. flexneri (Serogroup B)\nS. boydii (Serogroup C)\nS. sonnei (Serogroup D)\n\n3rd most common cause of gastroenteritis after Salmonella and Campylobacter\nHumans are the only known host and reservoir (spread from infected food water-fecal-oral)\nSexual transmission (anal intercourse) and epidemiologically linked to azithromycin resistance"
  },
  {
    "objectID": "diarrhea.html#yersina",
    "href": "diarrhea.html#yersina",
    "title": "Infectious Diarrheal Diseases",
    "section": "Yersina",
    "text": "Yersina\n\nYersiniosis, causes by Yersinia entercolitica or Yersinia pseudotuberculosis is a zoonotic infection\nAssociated with unpasteurized milk, undercooked meat (especially pork), water contaminated with feces- pigs are common source of infection\nAfter ingestion, organism proliferates in lymphoid tissue of small intestine where it may cause hyperemia, neutrophil infiltration and ulceration\nPatients may present with pharyngitis (20%)- not seen with other causes of gastroenteritis\n\nThroat cultures may be positive"
  },
  {
    "objectID": "diarrhea.html#vibrio",
    "href": "diarrhea.html#vibrio",
    "title": "Infectious Diarrheal Diseases",
    "section": "Vibrio",
    "text": "Vibrio\n\nNatural inhabitants of brackish and salt water worldwide\nDiarrhea causing species are:\n\nVibrio cholerae (causative agent of cholera)\n\nEpidemic: V. cholerae O1 (clasical and El Tor)\n\nNew Serogroup 0139 Bengal merged from Southern India\n\n\nVibrio parahaemalyticus\nVibrio vulnificus (can cause diarrhea, but isolated from blood and tissues of patients with liver disease\nVibrio"
  },
  {
    "objectID": "diarrhea.html#others",
    "href": "diarrhea.html#others",
    "title": "Infectious Diarrheal Diseases",
    "section": "Others",
    "text": "Others\n\nAeromonas\nPlesiomonas shigelloides\nListeria (1% but associated with outbreaks in summer-high risk foods, unpasteurized milk\n\nCan cause invasive disease in pregnant and immunocompromised\nOral amoxicillin or trimethoprim/SMX"
  },
  {
    "objectID": "diarrhea.html#parasites",
    "href": "diarrhea.html#parasites",
    "title": "Infectious Diarrheal Diseases",
    "section": "Parasites",
    "text": "Parasites\n\nConsider if diarrhea lasts &gt; 14 days\nGiardia, Cyclospora, Cryptosporidium spp.\nMay be assocaited with community waterborne outbreaks\nDiagnosed by stool culture and examination for ova, cysts and parasites\n\nShed intermittently: May need 3 consecutive samples"
  },
  {
    "objectID": "diarrhea.html#toxins",
    "href": "diarrhea.html#toxins",
    "title": "Infectious Diarrheal Diseases",
    "section": "Toxins",
    "text": "Toxins\n\nClostridium perfringes spores poorly cooked or stored meat\n\nType A : cause of outbreaks- infection through poorly heated food and meat products (spores survive reheating)\nTypes B and D do not produce disease\nType C : Hemorrhagic necrosis of the jejunum (pigbel disease) following consumption of pork products. Trypsin inhibitors in sweet potatoes may inhibit breakdown of toxin and potentiates the disease\n\nStaphylococcus aureus toxin\nBacillus cereus (rice) toxin"
  },
  {
    "objectID": "diarrhea.html#clostridium-perfringes",
    "href": "diarrhea.html#clostridium-perfringes",
    "title": "Infectious Diarrheal Diseases",
    "section": "Clostridium perfringes",
    "text": "Clostridium perfringes"
  },
  {
    "objectID": "diarrhea.html#staphylococcus-aerues",
    "href": "diarrhea.html#staphylococcus-aerues",
    "title": "Infectious Diarrheal Diseases",
    "section": "Staphylococcus aerues",
    "text": "Staphylococcus aerues"
  },
  {
    "objectID": "diarrhea.html#bacillus-cereus",
    "href": "diarrhea.html#bacillus-cereus",
    "title": "Infectious Diarrheal Diseases",
    "section": "Bacillus cereus",
    "text": "Bacillus cereus"
  },
  {
    "objectID": "diarrhea.html#scombroid",
    "href": "diarrhea.html#scombroid",
    "title": "Infectious Diarrheal Diseases",
    "section": "Scombroid",
    "text": "Scombroid\n\nFood poisoning associated with seafood\nCommonly misdiagnosed as allergy\nIncorrect storage above 4°C, resulting in bacterial overgrowth and build up of toxic levels of histamine and other biogenic amines by the bacterial enzyme histidine decarboxylase found in dark fish meat\n\nScombridae and Scoberesocidae: tuna (even open cans), mackerel, skip-jack, bonito, dolphin, tilapa, salmon, swordfish, trout, sardines\n\nHistamine is not broken down by cooking, freezing\n\nStoring fish at 20°C for 2-3 hours is enough to result in poisoning\n\nBacteria reposnsible: E. coli, K. pneumoniae, halophilic Vibrio sp., Proteus, Clostridium and Salmonella, and Shigella\nFish appear to have honey-combed scales and taste “peppery”, “bubbly” or “spicy”\nRaw milk contaminated before production of Swiss sheese results in siilar bacterial overgrowth and histamine build-up"
  },
  {
    "objectID": "diarrhea.html#ciguatera",
    "href": "diarrhea.html#ciguatera",
    "title": "Infectious Diarrheal Diseases",
    "section": "Ciguatera",
    "text": "Ciguatera\n\nFoodborne illness caused by consumption of reef fish (barracuda, amberjack, moray eel, some types of grouper, snapper, parrotfish) contaminated with multiple toxins, including ciguatera toxin, which arises from dinoflagellates\nToxins accumulate in flash and organs\nDo not look, smell or taste different unlike scombroid poisoning\nPresents with GI symptoms and neurologic signs without altered mental status"
  },
  {
    "objectID": "diarrhea.html#clinical-features-of-enteric-fever-1",
    "href": "diarrhea.html#clinical-features-of-enteric-fever-1",
    "title": "Infectious Diarrheal Diseases",
    "section": "Clinical features of enteric fever-1",
    "text": "Clinical features of enteric fever-1\n\nStepwise over a series of weeks:\n\nWeek 1: Fevers &gt; 40°C with bacteremia, chills, rigours, bradycardia with pulse temperature association (see FUO lecture)\n\nPatients may initially present with constipation, whereas diarrhea is more common in children and patients living with HIV\n\nWeek 2: Abdominal pain, “rose spots”"
  },
  {
    "objectID": "diarrhea.html#clinical-features-of-enteric-fever-2",
    "href": "diarrhea.html#clinical-features-of-enteric-fever-2",
    "title": "Infectious Diarrheal Diseases",
    "section": "Clinical features of enteric fever-2",
    "text": "Clinical features of enteric fever-2\n\n\nWeek 3: Abdominal perforation secondary to necrosis and lymphatic hyperplasia of Peye’s patches (uncommon in children &lt; 5 years), hepatosplenomegaly, intestinal bleeding and secondary bacteremia → septic shock\n\nExtraintestinal manifestations: headache 44-94% “typhoid encephalopathy”, altered sleep patterns, myelitis, acute psychosis, signs of upper neuron disease, ataxia, parkinsonism (but meningitis is rare)\nBacteremia can seen cardiovascular, hepatobiliary, respiratory, genitourinary nad musculoskeletal system\nLaboratory findings: leukopenia with anemia, but leukeocytosis seen in children or with intestinal perforation\n\nMost patients resolve the infection in weeks to months without antibiotic therapy (cause of FUO) although death can occur with abdominal perforation"
  },
  {
    "objectID": "diarrhea.html#how-to-establish-typhoid-fever-diagnosis",
    "href": "diarrhea.html#how-to-establish-typhoid-fever-diagnosis",
    "title": "Infectious Diarrheal Diseases",
    "section": "How to establish typhoid fever diagnosis?",
    "text": "How to establish typhoid fever diagnosis?\n\n\nBlood and stool cultures (blood positive in 40-80%; stool 30-40%)\nBone marrow &gt; 90% recovery- considered for complicated cases or if unresponsive to treatment (will remain positive at least 5 days after antibiotic treatment)\nSerology (anti-S. typhi antibiotics ) less frequently used"
  },
  {
    "objectID": "diarrhea.html#typhoid-fever-treatment",
    "href": "diarrhea.html#typhoid-fever-treatment",
    "title": "Infectious Diarrheal Diseases",
    "section": "Typhoid fever treatment",
    "text": "Typhoid fever treatment\n\nFluorquinolone and 3rd generation cephalosporin resistance increasing in SE Asia\nHowever, most strains still susceptible to 3rd generation cephalosporins and azithromycin, treatment of 10-14 days required\n\nif no resistance suscepted, ciprofloxacin, which is bactericidal and concentrates intracellularly and in the bile will results in more rapid intraceiilar clearnace than beta-lactams\nAlternatives azithromycin (5 days), ampicillin, tremimethoprim-sulfamathoxazole\n\nIn uncomplicated cases, patients will defervesce in 4-6 days\nRelapse usually occurs after 2-3 weeks following fever resolution (depending on antibiotics) and requires further antibiotic treatment"
  },
  {
    "objectID": "diarrhea.html#clinical-features-of-shigella-infections",
    "href": "diarrhea.html#clinical-features-of-shigella-infections",
    "title": "Infectious Diarrheal Diseases",
    "section": "Clinical features of Shigella infections",
    "text": "Clinical features of Shigella infections\n\nInvade the colon mucosa cells causing abscess formation and ulceration\nSpread from cell to cell and produce enterotoxcins (plasmid-encoded ShET2), chromosomally-encoded ShET (S. flexneri) and shiga toxicn (Stx) (S. dysenteriae)\n\nToxins result in loss of water and solutes\nCause HUS similar to E.Coli 0157 (Stx toxin)- 8% of children"
  },
  {
    "objectID": "diarrhea.html#clostridium-perfringes-toxin",
    "href": "diarrhea.html#clostridium-perfringes-toxin",
    "title": "Infectious Diarrheal Diseases",
    "section": "Clostridium perfringes toxin",
    "text": "Clostridium perfringes toxin"
  },
  {
    "objectID": "diarrhea.html#staphylococcus-aureus-toxin",
    "href": "diarrhea.html#staphylococcus-aureus-toxin",
    "title": "Infectious Diarrheal Diseases",
    "section": "Staphylococcus aureus toxin",
    "text": "Staphylococcus aureus toxin"
  },
  {
    "objectID": "diarrhea.html#bacillus-cereus-toxin",
    "href": "diarrhea.html#bacillus-cereus-toxin",
    "title": "Infectious Diarrheal Diseases",
    "section": "Bacillus cereus toxin",
    "text": "Bacillus cereus toxin"
  },
  {
    "objectID": "diarrhea.html#diagnosis-and-treaetment-of-shigella-infections",
    "href": "diarrhea.html#diagnosis-and-treaetment-of-shigella-infections",
    "title": "Infectious Diarrheal Diseases",
    "section": "Diagnosis and treaetment of Shigella infections",
    "text": "Diagnosis and treaetment of Shigella infections\n\nBest cultyre yield from mucous stool\nWhite blood cells and red blood cells commonly seen by microbiology\nPCR testing of Shigella, but culture important for susceptibility testing\n\nAsia and Africa: 20-30% resistance; TMP/SMX 65-85%\nAntibiotic decrease duration of shedding and symptoms by 2 days\n\nMost infections are self limiting, but antibiotics are considerd for:\n\nImmunocompromised, including patients living with HIV\nBacteremia or extraintestinal disease\nPatients at risk transmitting to others (Food handlers, residential home workers, nursery staff)\n\nDrug of choice (no resistance concerns): fluoroquinolone; or ceftriaxone pending susceptibilities"
  },
  {
    "objectID": "diarrhea.html#diagnosis-and-treatment-of-shigella-infections",
    "href": "diarrhea.html#diagnosis-and-treatment-of-shigella-infections",
    "title": "Infectious Diarrheal Diseases",
    "section": "Diagnosis and treatment of Shigella infections",
    "text": "Diagnosis and treatment of Shigella infections\n\nBest culture yield from mucous stool\nWhite blood cells and red blood cells commonly seen by microbiology\nPCR testing of Shigella, but culture important for susceptibility testing\n\nAsia and Africa: 20-30% resistance; TMP/SMX 65-85%\nAntibiotic decrease duration of shedding and symptoms by 2 days\n\nMost infections are self limiting, but antibiotics are considerd for:\n\nImmunocompromised, including patients living with HIV\nBacteremia or extraintestinal disease\nPatients at risk transmitting to others (Food handlers, residential home workers, nursery staff)\n\nDrug of choice (no resistance concerns): fluoroquinolone; or ceftriaxone pending susceptibilities"
  },
  {
    "objectID": "diarrhea.html#yersina-presentation",
    "href": "diarrhea.html#yersina-presentation",
    "title": "Infectious Diarrheal Diseases",
    "section": "Yersina presentation",
    "text": "Yersina presentation\n\nIncubation period 1-14 days\nLocalization of pain to right lower quandrant may be a diagnostic clue\nHematogenous spread can lead to abscess infmation in the liver, spleen, mesenteric adenitis, terminal ileitis, pseudoappendicitis\nPost-infectious immunologic sequale (reactive arthritis, erythyma nodosum)\nNo established data that antibiotic treatment is beneficial for uncomplicated disease, fluroquinolones may be given- IV ceftriaxone or cprofloxacin in septic patients"
  },
  {
    "objectID": "diarrhea.html#vibrio-1",
    "href": "diarrhea.html#vibrio-1",
    "title": "Infectious Diarrheal Diseases",
    "section": "Vibrio",
    "text": "Vibrio"
  },
  {
    "objectID": "diarrhea.html#vibrio-transmission",
    "href": "diarrhea.html#vibrio-transmission",
    "title": "Infectious Diarrheal Diseases",
    "section": "Vibrio transmission",
    "text": "Vibrio transmission\n\nfeco-oral\nCholera outbreaks are most often associated with contaminated water and contaminated food, particuliarly undercooked or raw seafood\nV. cholerae O1 and O139 are producers of cholera toxin (CT)"
  },
  {
    "objectID": "diarrhea.html#john-snow",
    "href": "diarrhea.html#john-snow",
    "title": "Infectious Diarrheal Diseases",
    "section": "John Snow",
    "text": "John Snow"
  },
  {
    "objectID": "diarrhea.html#john-snow-london",
    "href": "diarrhea.html#john-snow-london",
    "title": "Infectious Diarrheal Diseases",
    "section": "John Snow, London",
    "text": "John Snow, London"
  },
  {
    "objectID": "diarrhea.html#vibrio-clinical-features",
    "href": "diarrhea.html#vibrio-clinical-features",
    "title": "Infectious Diarrheal Diseases",
    "section": "Vibrio clinical features",
    "text": "Vibrio clinical features\n\n\nProfuse, watery diarrhea “rice water stool”\nMucous, but no blood present\nIncubation: A few hours to a few days\nSignificant hypovolemia and electrolyte abnormalities can occur within a few hours of symptom onset\nAbdominal discomfort, borborygmi, and vomiting are common"
  },
  {
    "objectID": "diarrhea.html#vibrio-treatment",
    "href": "diarrhea.html#vibrio-treatment",
    "title": "Infectious Diarrheal Diseases",
    "section": "Vibrio treatment",
    "text": "Vibrio treatment\n\nAntibiotics shorten the duration of diarrhea, reduce the volume of stool losses, and decrease the duration of V. cholera shedding\nTreatment options include macrolides, fluoroquinolones, tetracyclines based on local resistance profile"
  },
  {
    "objectID": "diarrhea.html#vibrio-vulficans",
    "href": "diarrhea.html#vibrio-vulficans",
    "title": "Infectious Diarrheal Diseases",
    "section": "Vibrio vulficans",
    "text": "Vibrio vulficans\n\nIngestion of shellfish may give rise to cellulitis and bullous lesions (especially in cirrhotic patients)\nEspecially in water temperatures above 20°C (only eat raw oysters in months that end with “R”)\nInfection can progress to invasive disease with bacteremia and systemic disease in immunosuppressed, those with cirrhotic disease or hemochromatosis\nHigh mortality rate with septicemia- exceeds 90% if patients present with hypotension\nPatients require immediate antibiotic therapy (tetracycline + 3rd generation cephalosporin) and transfer to the ICU - Fluroquinolone monotherapy alternative"
  },
  {
    "objectID": "diarrhea.html#clostridioides-formally-clostridium-difficile",
    "href": "diarrhea.html#clostridioides-formally-clostridium-difficile",
    "title": "Infectious Diarrheal Diseases",
    "section": "Clostridioides (formally Clostridium) difficile",
    "text": "Clostridioides (formally Clostridium) difficile\n\nWill be discussed separate lecture in greater detail\nGram-positive anaerobic bacillus that is spore forming and able to produce toxin\nC. difficile causes an antibiotic-associated inflammatory colitis and in the commonest cause of healthcare-associated diarrhea\nInfection requires spores to be acquired and for gut microbiota to be disrupted, usually through preceding antibiotic therapy\nToxin A causes inflammation with intestinal fluid secretin and dmage to mucosa\nToxin B, more potent than Toxin A, acts as a virulence factor\nDiagnosis is established with 2-step process: glutamate dehydrogenase (GDH) and PCR testing or other NAAT for toxin\nTreatment: Oral vancomycin or fidoxamine &gt; metronidazole"
  },
  {
    "objectID": "diarrhea.html#scombroid-rash",
    "href": "diarrhea.html#scombroid-rash",
    "title": "Infectious Diarrheal Diseases",
    "section": "Scombroid rash",
    "text": "Scombroid rash\n\nSpec et al. Comprehensive review of infectious diseases"
  },
  {
    "objectID": "diarrhea.html#management-summary",
    "href": "diarrhea.html#management-summary",
    "title": "Infectious Diarrheal Diseases",
    "section": "Management summary",
    "text": "Management summary"
  },
  {
    "objectID": "diarrhea.html#patient-medical-history-1",
    "href": "diarrhea.html#patient-medical-history-1",
    "title": "Infectious Diarrheal Diseases",
    "section": "Patient Medical History",
    "text": "Patient Medical History\n\n\nDuration of symptoms\nFrequency and characteristics of stool\nAssociated Symptoms\nEvidence of extracellular volume depletion (e.g., dark of scan urine, decreased skin turgor, orthostatic hypotension)"
  },
  {
    "objectID": "diarrhea.html#treatment",
    "href": "diarrhea.html#treatment",
    "title": "Infectious Diarrheal Diseases",
    "section": "Treatment",
    "text": "Treatment\n\nAntibiotic specific recommendations per pathogen.\n\nFluroquinolones, azithromycin, ceftriaxones (amoxicillin), trimethoprim-sulfamethoxazole, doxycycline\n\nOral rehydration when possible vs. IV"
  },
  {
    "objectID": "diarrhea.html#fluid-repletion",
    "href": "diarrhea.html#fluid-repletion",
    "title": "Infectious Diarrheal Diseases",
    "section": "Fluid repletion",
    "text": "Fluid repletion\n\n\nThe most critical therapy in diarrheal illness is rehydration, preferably by the oral route, with solutions that contain water, salt, and sugar\nDiluted fruit juices and flavored soft drinks along with saltine crackers and broths or soups may meet the fluid and salt needs in patients with mild illness\nThe electrolyte concentrations of fluids used for sweat replacement (eg, Gatorade) are not equivalent to oral rehydration solutions, although they may be sufficient for the otherwise healthy patient with diarrhea who is not hypovolemic.\nOral rehydration solutions (ORS), including standard World Health Organization ORS or commercial ORS, such as Rehydralyte and Ceralyte, may be more appropriate in patients with more severe diarrheal disease. They should be used both to replete a volume depleted patient and also to maintain adequate volume status once replete."
  },
  {
    "objectID": "diarrhea.html#composition-of-oral-rehydration-solutions-orsc-and-commonly-used-beverages",
    "href": "diarrhea.html#composition-of-oral-rehydration-solutions-orsc-and-commonly-used-beverages",
    "title": "Infectious Diarrheal Diseases",
    "section": "Composition of oral rehydration solutions (ORSC) and commonly used beverages",
    "text": "Composition of oral rehydration solutions (ORSC) and commonly used beverages\n\n\n\n\n\n\n\n\n\n\n\n\nCarbohydrate (g/L)\nmEq/L\n\n\nOsmolarity (mOSM/kg H2O)\n\n\n\n\nSodium\nPotassium\nBase (HCO3–)\n\n\n\n\n\nOral rehydration solutions\n\n\n\n\n\n\n\nCeraLyte\n40\n70\n20\n10\n235\n\n\nEnfalyte\n30\n50\n25\n30\n200\n\n\nPedialyte\n25\n45\n20\n30\n250\n\n\nRehydralyte\n25\n75\n20\n30\n310\n\n\nWHO (1975)\n20\n90\n30\n30\n310\n\n\nWHO (2002)\n13.5\n75\n20\n30\n245\n\n\nCommonly Used Beverages (not appropriate for repletion therapy)\n\n\n\n\n\n\n\nApple juice\n100 to 150\n3\n20\n0\n700\n\n\nChicken broth\n0\n250\n5\n0\n450\n\n\nColas\n100 to 150\n2\n0.1\n13\n550\n\n\nGatorade\n45\n20\n3\n3\n330\n\n\nGinger Ale\n90\n3.5\n0.1\n3.6\n565\n\n\nTea\n0\n0\n0\n0\n5\n\n\n\nORSs were developed following the realization that, in many small bowel diarrheal illnesses, intestinal glucose absorption via sodium-glucose cotransport remains intact. Thus, in diarrheal disease caused by any organism that depends on small bowel secretory processes, the intestine remains able to absorb water if glucose and salt are also present to assist in the transport of water from the intestinal lumen"
  },
  {
    "objectID": "febrileneutropenia.html#lecture-slides",
    "href": "febrileneutropenia.html#lecture-slides",
    "title": "Febrile neutropenia",
    "section": "",
    "text": "slides"
  },
  {
    "objectID": "immunosuppression.html",
    "href": "immunosuppression.html",
    "title": "Infections in the Immunocompromised Host",
    "section": "",
    "text": "Russell Lewis  Associate Professor, Infectious Diseases  Department of Molecular Medicine  MEP 2491 Infectious Diseases  13 March 2023"
  },
  {
    "objectID": "immunosuppression.html#parasitic-disesease-malaria-and-leishemoniasis",
    "href": "immunosuppression.html#parasitic-disesease-malaria-and-leishemoniasis",
    "title": "Parasitic Infections: Malaria and Leishamoniasis",
    "section": "Parasitic Disesease Malaria and Leishemoniasis",
    "text": "Parasitic Disesease Malaria and Leishemoniasis\n\n\nRussell Lewis  Associate Professor, Infectious Diseases  Department of Molecular Medicine  MEP 2491 Infectious Diseases  2 May 2023"
  },
  {
    "objectID": "Malaria.html#parasitic-diseases-malaria-and-leishmaniasis",
    "href": "Malaria.html#parasitic-diseases-malaria-and-leishmaniasis",
    "title": "Malaria and Leishmaniasis",
    "section": "Parasitic Diseases: Malaria and Leishmaniasis",
    "text": "Parasitic Diseases: Malaria and Leishmaniasis\n\n\nRussell Lewis  Associate Professor, Infectious Diseases  Department of Molecular Medicine  MEP 2491 Infectious Diseases  2 May 2023"
  },
  {
    "objectID": "Malaria.html#objectives",
    "href": "Malaria.html#objectives",
    "title": "Malaria and Leishmaniasis",
    "section": "Objectives",
    "text": "Objectives"
  },
  {
    "objectID": "Malaria.html#references",
    "href": "Malaria.html#references",
    "title": "Malaria and Leishmaniasis",
    "section": "References",
    "text": "References\n\n\n\n\n\n\n\nFairhurst, Rick, Wellems, Thomas. Malaria (plasmodium species). 8th ed., Elsivier; 2015.\n\n\nIdro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. The Lancet Neurology 2005;4:827–40. https://doi.org/10.1016/S1474-4422(05)70247-7.\n\n\nKwiatkowski DP. How malaria has affected the human genome and what human genetics can teach us about malaria. American Journal of Human Genetics 2005;77:171–92.\n\n\nPhillips MA, Burrows JN, Manyando C, Huijsduijnen RH van, Van Voorhis WC, Wells TNC. Malaria. Nature Reviews Disease Primers 2017b;3:17050. https://doi.org/10.1038/nrdp.2017.50.\n\n\nPhillips MA, Burrows JN, Manyando C, Huijsduijnen RH van, Van Voorhis WC, Wells TNC. Malaria. Nature Reviews Disease Primers 2017a;3:17050. https://doi.org/10.1038/nrdp.2017.50.\n\n\nPhillips MA, Burrows JN, Manyando C, Huijsduijnen RH van, Van Voorhis WC, Wells TNC. Malaria. Nature Reviews Disease Primers 2017c;3:17050. https://doi.org/10.1038/nrdp.2017.50.\n\n\nTatem AJ, Rogers DJ, Hay SI. Estimating the malaria risk of african mosquito movement by air travel. Malaria Journal 2006;5:57. https://doi.org/10.1186/1475-2875-5-57."
  },
  {
    "objectID": "Malaria.html#parasitic-diseases-malaria-and-leishmaniasis-background-imageimages_malariamosquito.png-background-opacity-0.5",
    "href": "Malaria.html#parasitic-diseases-malaria-and-leishmaniasis-background-imageimages_malariamosquito.png-background-opacity-0.5",
    "title": "Malaria and Leishmaniasis",
    "section": "Parasitic Diseases: Malaria and Leishmaniasis {background-image=“/images_malaria/mosquito.png” background-opacity 0.5}",
    "text": "Parasitic Diseases: Malaria and Leishmaniasis {background-image=“/images_malaria/mosquito.png” background-opacity 0.5}\n\n\nRussell Lewis  Associate Professor, Infectious Diseases  Department of Molecular Medicine  MEP 2491 Infectious Diseases  2 May 2023"
  },
  {
    "objectID": "Malaria.html#world-malaria-day",
    "href": "Malaria.html#world-malaria-day",
    "title": "Malaria and Leishmaniasis",
    "section": "World Malaria Day",
    "text": "World Malaria Day"
  },
  {
    "objectID": "Malaria.html#protozoa-first-animals",
    "href": "Malaria.html#protozoa-first-animals",
    "title": "Malaria and Leishmaniasis",
    "section": "Protozoa “first animals”",
    "text": "Protozoa “first animals”\n\n\n\n\n\n\n\n\nMeans of spread\nHabitat\nExtracellular\nIntracellular\n\n\n\n\nInsect-borne*\nAfrican trypanosome (blood)\nPlasmodium (liver, red blood cells)\nLeishmania (macrophage)\nSouth-America trypanosome (macrophage, muscle, nerve)\n\n\nWater-born\nAmoeba (gut)\nGiardia (gut)\nCryptosporidium (gut)\nIsospora (gut)\nTrichomonas (urogenital)\nToxoplasma (macrophage)\n\n\n\n\n\n*The protozoa carried by inset vectors are mainly confined to tropics by the distribution of of the vectors"
  },
  {
    "objectID": "Malaria.html#plasmodium-spp.",
    "href": "Malaria.html#plasmodium-spp.",
    "title": "Malaria and Leishmaniasis",
    "section": "Plasmodium spp.",
    "text": "Plasmodium spp.\n\n\n\n\n\n\n\nImage: Wikipedia"
  },
  {
    "objectID": "Malaria.html#four-species-of-plasmodium-infection-humans",
    "href": "Malaria.html#four-species-of-plasmodium-infection-humans",
    "title": "Malaria and Leishmaniasis",
    "section": "Four species of Plasmodium infection humans",
    "text": "Four species of Plasmodium infection humans\n\nPlasmodium falciparum (malignant tertain)\n\nMost deadly (1 million deaths per year- anaemia and cerebral malaria)\nSequestration- parasitized RBCs: glomerulonephritis, hypoglycaemia, pulmonary edema\nAlmost all deaths are caused by this species\n\n\n\n(Fairhurst, Rick and Wellems, Thomas, 2015)"
  },
  {
    "objectID": "Malaria.html#four-species-of-plasmodium-infection-humans-1",
    "href": "Malaria.html#four-species-of-plasmodium-infection-humans-1",
    "title": "Malaria and Leishmaniasis",
    "section": "Four species of Plasmodium infection humans",
    "text": "Four species of Plasmodium infection humans\n\n\n\n\n\n\n\n\n\n\nPlasmodium spp.\nLiver stage\nBlood cycle and fever peaks\nDisease features\n\n\n\n\nP. falciprium\n6-14 days\n48h (tertian)\nMajor complications, fatal without treatment\n\n\nP. vivax\n12-17 days\n48h\nSeldom fatal\n\n\nP. malariae\n13-40 days\n72h (quartan)\nNephrotic syndrome\n\n\nP. ovale\n9-18 days\n50h\n\n\n\nP. knowlowsi\n9-12 days\n24h\nSoutheast Asia, monkey"
  },
  {
    "objectID": "Malaria.html#the-impact-of-malaria-on-humans-is-staggering",
    "href": "Malaria.html#the-impact-of-malaria-on-humans-is-staggering",
    "title": "Malaria and Leishmaniasis",
    "section": "The impact of malaria on humans is staggering",
    "text": "The impact of malaria on humans is staggering\n\nKills roughly 2000 people per day, most of whom are children in Africa\nStrongest known force for evolutionary selection in the recent history of the human genome.\n\nMalaria is the evolutionary driving force behind sickle-cell disease, thalassemia, glucose-6-phosphatase deficiency, and other erythrocyte defects that together comprise the most common Mendelian diseases of humankind\n\nMalaria was once prevalent throughout much of the inhabited world, but has been eliminated from the USA and Canada, Europe, and Russia\nMalaria prevalence resurged in tropical countries from the 1970s to the 1990s because of a combination of relaxation of control efforts, increasing antimalarial drug resistance, and insecticide resistance in the mosquito vectors\n\n\n\n(Kwiatkowski, 2005)"
  },
  {
    "objectID": "Malaria.html#malaria-endemic-regions",
    "href": "Malaria.html#malaria-endemic-regions",
    "title": "Malaria and Leishmaniasis",
    "section": "Malaria endemic regions",
    "text": "Malaria endemic regions\n\n\n\n\n\n\n\n\n(Phillips et al., 2017a)"
  },
  {
    "objectID": "Malaria.html#malaria-in-preganancy",
    "href": "Malaria.html#malaria-in-preganancy",
    "title": "Malaria and Leishmaniasis",
    "section": "Malaria in preganancy",
    "text": "Malaria in preganancy"
  },
  {
    "objectID": "Malaria.html#malaria-in-pregnancy",
    "href": "Malaria.html#malaria-in-pregnancy",
    "title": "Malaria and Leishmaniasis",
    "section": "Malaria in pregnancy",
    "text": "Malaria in pregnancy"
  },
  {
    "objectID": "Malaria.html#the-impact-of-malaria-on-humans-is-is-staggering",
    "href": "Malaria.html#the-impact-of-malaria-on-humans-is-is-staggering",
    "title": "Malaria and Leishmaniasis",
    "section": "The impact of malaria on humans is  is staggering",
    "text": "The impact of malaria on humans is  is staggering\n\n\nKills roughly 2000 people per day, most of whom are children in Africa\nThe strongest documented force for evolutionary selection in the recent history of the human genome\n\nMalaria is the evolutionary driving force behind the most common Mendelian diseases of humankind: sickle-cell disease, thalassemia, glucose-6-phosphatase deficiency, and other erythrocyte defects\n\nMalaria was once prevalent throughout much of the inhabited world, but has been eliminated from the USA and Canada, Europe, and Russia (chloroquine-based treatment, large-scale insecticide using DDT)\n\nMalaria prevalence resurged in tropical countries from the 1970s to the 1990s because of a combination of relaxation of control efforts, increasing antimalarial drug resistance, and insecticide resistance in the mosquito vectors\nMore selective vector control approaches (insecticide bed nets, indoor residual spraying) have led to a reduction in some areas of the world in the last 20 years\n\nGrowing resistance to insecticides in mosquitoes (Anopheles gambiae)\n\nOf the 78 countries that monitor insecticide resistance, 60 have reported resistance\nIncreasing resistance to first-line XXXXX\n\n\n\n\n(Kwiatkowski, 2005; Phillips et al., 2017a)"
  },
  {
    "objectID": "Malaria.html#the-vector",
    "href": "Malaria.html#the-vector",
    "title": "Malaria and Leishmaniasis",
    "section": "The vector",
    "text": "The vector\n\n\nMalaria is transmitted by the bite of Plasmodium-infected female mosquitoes of the Anophelus genus"
  },
  {
    "objectID": "Malaria.html#plasmodium-infection-humans",
    "href": "Malaria.html#plasmodium-infection-humans",
    "title": "Malaria and Leishmaniasis",
    "section": "Plasmodium infection humans",
    "text": "Plasmodium infection humans\n\n\n\nPlasmodium falciparum (malignant tertain)\n\nMost deadly (1 million deaths per year- anaemia and cerebral malaria)\nSequestration- parasitized RBCs: glomerulonephritis, hypoglycaemia, pulmonary edema\nAlmost all deaths are caused by this species"
  },
  {
    "objectID": "Malaria.html#five-species-of-plasmodium-infection-humans",
    "href": "Malaria.html#five-species-of-plasmodium-infection-humans",
    "title": "Malaria and Leishmaniasis",
    "section": "Five species of Plasmodium infection humans",
    "text": "Five species of Plasmodium infection humans\n\n\n\n\n\n\n\n\n\n\nPlasmodium spp.\nLiver stage\nBlood cycle and fever peaks\nDisease features\n\n\n\n\nP. falciprium\n6-14 days\n48h (tertian)\nMajor complications, fatal without treatment\n\n\nP. vivax\n12-17 days\n48h\nSeldom fatal\n\n\nP. malariae\n13-40 days\n72h (quartan)\nNephrotic syndrome\n\n\nP. ovale\n9-18 days\n50h\n\n\n\nP. knowlowsi\n9-12 days\n24h\nSoutheast Asia, monkey"
  },
  {
    "objectID": "Malaria.html#section",
    "href": "Malaria.html#section",
    "title": "Malaria and Leishmaniasis",
    "section": "",
    "text": "Image: Wikipedia"
  },
  {
    "objectID": "Malaria.html#five-species-of-plasmodium-infection-in-humans",
    "href": "Malaria.html#five-species-of-plasmodium-infection-in-humans",
    "title": "Malaria and Leishmaniasis",
    "section": "Five species of Plasmodium infection in humans",
    "text": "Five species of Plasmodium infection in humans\n\n\n\n\n\n\n\n\n\n\nPlasmodium spp.\nLiver stage\nBlood cycle and fever peaks\nDisease features\n\n\n\n\nP. falciprium\n6-14 days\n48h (tertian)\nMajor complications, fatal without treatment\n\n\nP. vivax\n12-17 days\n48h (tertian)\nSeldom fatal, but can better survive unfavourable temperatures and remain dormant in the liver\n\n\nP. malariae\n13-40 days\n72h (quartan)\nNephrotic syndrome\n\n\nP. ovale\n9-18 days\n48h (tertian)\n\n\n\nP. knowlowsi\n9-12 days\n24h (quotidian)\nSoutheast Asia, monkey"
  },
  {
    "objectID": "Malaria.html#plasmodium-spp.-life-cycle",
    "href": "Malaria.html#plasmodium-spp.-life-cycle",
    "title": "Malaria and Leishmaniasis",
    "section": "Plasmodium spp. life cycle",
    "text": "Plasmodium spp. life cycle\n\n\n\n\n\n\n\n(Phillips et al., 2017b)"
  },
  {
    "objectID": "Malaria.html#malaria--acquired-immunity",
    "href": "Malaria.html#malaria--acquired-immunity",
    "title": "Malaria and Leishmaniasis",
    "section": "Malaria- acquired immunity",
    "text": "Malaria- acquired immunity\n\n\nMediated by IgG antibodies against surface proteins of sporozoite (blocking hepatocyte invasion)\n\nAntibody-dependent cellular cytotoxicity, opsonisation for uptake, destruction by splenic macrophages, interference with PfEMP-1 mediated cytoadhearance interactions\n\nImmunity not sterilizing, instead “disease-controlling immunity” despite presence of parasites in bloodstream\nImmunity increases with age, cumulative episodes and time living in endemic area\n\nShort-lived without continued exposure to different P. falciparum variants\nAntigen switching results in new waves of parasitemia, escape from antibody responses\nDisease controlling immunity (premunition) after repeated infection episodes associated with development of antibody repertoire that recognizes the full spectrum PfEMP-1 variant antigens"
  },
  {
    "objectID": "Malaria.html#section-1",
    "href": "Malaria.html#section-1",
    "title": "Malaria and Leishmaniasis",
    "section": "",
    "text": "Splenomegaly common in malaria (removal of infected erythrocytes) but contributed to anaemia\n\nSplenectomised patients develop extremely high parasite loads"
  },
  {
    "objectID": "Malaria.html#malaria-immunity",
    "href": "Malaria.html#malaria-immunity",
    "title": "Malaria and Leishmaniasis",
    "section": "Malaria immunity",
    "text": "Malaria immunity\n\nSplenomegaly common in malaria (removal of infected erythrocytes) but contributed to anaemia\n\nSplenectomised patients develop extremely high parasite loads"
  },
  {
    "objectID": "Malaria.html#the-pathogen",
    "href": "Malaria.html#the-pathogen",
    "title": "Malaria and Leishmaniasis",
    "section": "The pathogen",
    "text": "The pathogen"
  },
  {
    "objectID": "Malaria.html#malaria-death-rates-in-2021",
    "href": "Malaria.html#malaria-death-rates-in-2021",
    "title": "Malaria and Leishmaniasis",
    "section": "Malaria death rates in 2021",
    "text": "Malaria death rates in 2021\n\n\nSource: Our World in Data"
  },
  {
    "objectID": "Malaria.html#underlying-conditions-associated-with-severe-malaria",
    "href": "Malaria.html#underlying-conditions-associated-with-severe-malaria",
    "title": "Malaria and Leishmaniasis",
    "section": "Underlying conditions associated with severe malaria",
    "text": "Underlying conditions associated with severe malaria\n\nSplenectomy - high parasite loads\n\nSplenomegaly common in malaria (removal of infected erythrocytes) but contributes to anaemia associated with disease\n\nPregnancy"
  },
  {
    "objectID": "Malaria.html#malaria-deaths-by-age",
    "href": "Malaria.html#malaria-deaths-by-age",
    "title": "Malaria and Leishmaniasis",
    "section": "Malaria deaths by age",
    "text": "Malaria deaths by age\n\n\nSource: Our World in Data"
  },
  {
    "objectID": "Malaria.html#malaria-deaths-by-age-1",
    "href": "Malaria.html#malaria-deaths-by-age-1",
    "title": "Malaria and Leishmaniasis",
    "section": "Malaria deaths by age",
    "text": "Malaria deaths by age\n\n\nSource: Our World in Data"
  },
  {
    "objectID": "Malaria.html#share-of-children-with-fever-receiving-appropriate-anti-malarial-drug",
    "href": "Malaria.html#share-of-children-with-fever-receiving-appropriate-anti-malarial-drug",
    "title": "Malaria and Leishmaniasis",
    "section": "Share of children with fever receiving appropriate anti-malarial drug",
    "text": "Share of children with fever receiving appropriate anti-malarial drug\n\n\nSource: Our World in Data"
  },
  {
    "objectID": "Malaria.html#trends-in-malaria-death-rates-in-2021",
    "href": "Malaria.html#trends-in-malaria-death-rates-in-2021",
    "title": "Malaria and Leishmaniasis",
    "section": "Trends in Malaria death rates in 2021",
    "text": "Trends in Malaria death rates in 2021\n\n\nSource: Our World in Data\nImprovements due to"
  },
  {
    "objectID": "Malaria.html#pathogenesis",
    "href": "Malaria.html#pathogenesis",
    "title": "Malaria and Leishmaniasis",
    "section": "Pathogenesis",
    "text": "Pathogenesis"
  },
  {
    "objectID": "Malaria.html#clinical-presentation",
    "href": "Malaria.html#clinical-presentation",
    "title": "Malaria and Leishmaniasis",
    "section": "Clinical presentation",
    "text": "Clinical presentation\n\n\nFirst symptoms are typically experienced 2-4 weeks after mosquito bite\nAsexual replication in RBCs results in subsequent waves of merozoite and malaria endotoxin release (heamozoin and parasite DNA) → TNF-α and paroxysms of chills, fevers and sweats for several hours followed by extreme fatigue\nCycle repeats every:\n\n24 hours Plasmodium knowlesi\n48 hours Plasmodium falciparam, Plasmodium vivax, Plasmodium ovale\n72 hours Plasmodium malaria\n\nSome P. vivax and P. ovale can postpone development in liver as latent forms called hypnozoites (not eradicated by standard therapy e.g., chloroquine) directed against blood stages.\nHyponozoite development can resume months to years later leading to relapse\n\nRelapse can be prevented with primaquine, but only moderately effective"
  },
  {
    "objectID": "Malaria.html#plasmodium-falciparum",
    "href": "Malaria.html#plasmodium-falciparum",
    "title": "Malaria and Leishmaniasis",
    "section": "Plasmodium falciparum",
    "text": "Plasmodium falciparum\n\n\n\n\nSEM demonstrating effect of malaria parasite on host erythrocyte\n\n\n\n\n(Fairhurst, Rick and Wellems, Thomas, 2015)"
  },
  {
    "objectID": "Malaria.html#plasmodium-falciparum-1",
    "href": "Malaria.html#plasmodium-falciparum-1",
    "title": "Malaria and Leishmaniasis",
    "section": "Plasmodium falciparum",
    "text": "Plasmodium falciparum\n\n\nMost deadly (1 million deaths per year- anaemia and cerebral malaria)\nSequestration- parasitized RBCs: glomerulonephritis, hypoglycaemia, pulmonary edema\nAlmost all deaths are caused by this species\n\n\n\n\n(Fairhurst, Rick and Wellems, Thomas, 2015)"
  },
  {
    "objectID": "Malaria.html#complications-of-malaria",
    "href": "Malaria.html#complications-of-malaria",
    "title": "Malaria and Leishmaniasis",
    "section": "Complications of malaria",
    "text": "Complications of malaria\n\n\nHypoglycaemia (coma, convulsions)\n\nChildren: Impaired hepatic gluconeogenesis, increased glucose consumption in peripheral tissues and by parasites, normal insulin levels\nAdults: Hyperinsulinemia due to parasite stimulation of pancreatic islet cells or quinine/quinidine therapy\nDecreased food intake during prodromal period\n\nAnaemia\n\nIntra vascular lysis and phagocytic removal of infected erythrocytes\nTNF-α associated suppression of erythropoeitin\nNormochromic, normocytic anemia without robust reticolocyte response\n\nPulmonary oedema and respiratory distress\n\nNon-cardiogenic pulmonary oedema due to sequesterization of infected erythromyctes → inflammatory response → capillary permability → pulmonary oedema → hypoxia →acute lung injury → ARDS\nDyspne and increasing respiratory rate are features of impending pulmonary oedema and preclude other clinical (e.g., acessory muscle breathing) and radiologic signs (increased interestitial markings)\n\nMetabolic (lactic) acidosis\n\nReduced delivery of oxygen to tissues from combined effects of anaemia, sequesterization and hypovolemia\nShift from aerobic to anaerobic metabolism causes lactate levels to rise\nLactate clearance by liver reduced\n\nAcute renal failure"
  },
  {
    "objectID": "Malaria.html#airport-malaria",
    "href": "Malaria.html#airport-malaria",
    "title": "Malaria and Leishmaniasis",
    "section": "Airport Malaria",
    "text": "Airport Malaria\n\n\n(Tatem et al., 2006)"
  },
  {
    "objectID": "Malaria.html#rare-cases",
    "href": "Malaria.html#rare-cases",
    "title": "Malaria and Leishmaniasis",
    "section": "Rare cases",
    "text": "Rare cases\n\n“It’s the first time in my 30-year career that I’ve seen a case of malaria originating in Trentino,” said Dr Claudio Paternoster, an infectious diseases specialist at Trento’s Santa Chiara Hospital. Since the 1950s, Italy has not had a malaria problem because mosquito-infested marshes were drained. There is speculation that Sofia might have caught malaria from one of two children treated for it at the Trento hospital after 15 August. They had caught it in Africa, and recovered."
  },
  {
    "objectID": "Malaria.html#unusual-cases",
    "href": "Malaria.html#unusual-cases",
    "title": "Malaria and Leishmaniasis",
    "section": "Unusual cases",
    "text": "Unusual cases\n\n“It’s the first time in my 30-year career that I’ve seen a case of malaria originating in Trentino,” said Dr Claudio Paternoster, an infectious diseases specialist at Trento’s Santa Chiara Hospital. Since the 1950s, Italy has not had a malaria problem because mosquito-infested marshes were drained. There is speculation that Sofia might have caught malaria from one of two children treated for it at the Trento hospital after 15 August. They had caught it in Africa, and recovered."
  },
  {
    "objectID": "Malaria.html#airport-or-suitcase-associated-malaria",
    "href": "Malaria.html#airport-or-suitcase-associated-malaria",
    "title": "Malaria and Leishmaniasis",
    "section": "Airport or “suitcase-associated” malaria",
    "text": "Airport or “suitcase-associated” malaria\n\n\n\n(Tatem et al., 2006)"
  },
  {
    "objectID": "Malaria.html#malaria-complications",
    "href": "Malaria.html#malaria-complications",
    "title": "Malaria and Leishmaniasis",
    "section": "Malaria complications",
    "text": "Malaria complications\n\nCerebral malaria (intense sequesteraì"
  },
  {
    "objectID": "Malaria.html#host-traits-that-influence-disease-severity-besides-blood-disorders",
    "href": "Malaria.html#host-traits-that-influence-disease-severity-besides-blood-disorders",
    "title": "Malaria and Leishmaniasis",
    "section": "Host traits that influence disease severity (besides blood disorders)",
    "text": "Host traits that influence disease severity (besides blood disorders)\n\n\nSplenectomy - high parasite loads\n\nSplenomegaly common in malaria (removal of infected erythrocytes) but contributes to anaemia associated with disease\n\nPregnancy - parasites that express protein surface variant antigen 2-CSA (chondroitin sulphate-2, a glycoproteins expressed in the placenta) leading to infected red blood cell sequestration in the placenta\n\nIncreased risk of maternal and/or foetal death, miscarriage, inter-uterine growth retardation, low-birth weight, increased newborn mortality\n\nHIV (higher degree of parasetemia, moratlity)\nTuberculosis"
  },
  {
    "objectID": "Malaria.html#diagnosis-and-screening",
    "href": "Malaria.html#diagnosis-and-screening",
    "title": "Malaria and Leishmaniasis",
    "section": "Diagnosis and Screening",
    "text": "Diagnosis and Screening"
  },
  {
    "objectID": "Malaria.html#parasitaemia",
    "href": "Malaria.html#parasitaemia",
    "title": "Malaria and Leishmaniasis",
    "section": "Parasitaemia",
    "text": "Parasitaemia"
  },
  {
    "objectID": "Malaria.html#microscopic-images-of-parasite-infected-red-blood-cells",
    "href": "Malaria.html#microscopic-images-of-parasite-infected-red-blood-cells",
    "title": "Malaria and Leishmaniasis",
    "section": "Microscopic images of parasite infected red blood cells",
    "text": "Microscopic images of parasite infected red blood cells"
  },
  {
    "objectID": "Malaria.html#rapid-diagnostic-tests-rdts",
    "href": "Malaria.html#rapid-diagnostic-tests-rdts",
    "title": "Malaria and Leishmaniasis",
    "section": "Rapid diagnostic tests (RDTs)",
    "text": "Rapid diagnostic tests (RDTs)"
  },
  {
    "objectID": "Malaria.html#prevention-and-vulnerable-populations",
    "href": "Malaria.html#prevention-and-vulnerable-populations",
    "title": "Malaria and Leishmaniasis",
    "section": "Prevention and vulnerable populations",
    "text": "Prevention and vulnerable populations"
  },
  {
    "objectID": "Malaria.html#vector-control-methods",
    "href": "Malaria.html#vector-control-methods",
    "title": "Malaria and Leishmaniasis",
    "section": "Vector control methods",
    "text": "Vector control methods"
  },
  {
    "objectID": "Malaria.html#chemoprotection",
    "href": "Malaria.html#chemoprotection",
    "title": "Malaria and Leishmaniasis",
    "section": "Chemoprotection",
    "text": "Chemoprotection"
  },
  {
    "objectID": "Malaria.html#chemoprevention",
    "href": "Malaria.html#chemoprevention",
    "title": "Malaria and Leishmaniasis",
    "section": "Chemoprevention",
    "text": "Chemoprevention"
  },
  {
    "objectID": "Malaria.html#vaccines",
    "href": "Malaria.html#vaccines",
    "title": "Malaria and Leishmaniasis",
    "section": "Vaccines",
    "text": "Vaccines"
  },
  {
    "objectID": "Malaria.html#management",
    "href": "Malaria.html#management",
    "title": "Malaria and Leishmaniasis",
    "section": "Management",
    "text": "Management"
  },
  {
    "objectID": "Malaria.html#uncomplicated-malaria-vs.-complicated-malaria",
    "href": "Malaria.html#uncomplicated-malaria-vs.-complicated-malaria",
    "title": "Malaria and Leishmaniasis",
    "section": "Uncomplicated malaria vs. complicated malaria",
    "text": "Uncomplicated malaria vs. complicated malaria"
  },
  {
    "objectID": "Malaria.html#p.-falciparum-malaria",
    "href": "Malaria.html#p.-falciparum-malaria",
    "title": "Malaria and Leishmaniasis",
    "section": "P. falciparum malaria",
    "text": "P. falciparum malaria"
  },
  {
    "objectID": "Malaria.html#p.-vivax-malaria",
    "href": "Malaria.html#p.-vivax-malaria",
    "title": "Malaria and Leishmaniasis",
    "section": "P. vivax malaria",
    "text": "P. vivax malaria"
  },
  {
    "objectID": "Malaria.html#drug-resistance-1",
    "href": "Malaria.html#drug-resistance-1",
    "title": "Malaria and Leishmaniasis",
    "section": "Drug resistance-1",
    "text": "Drug resistance-1"
  },
  {
    "objectID": "Malaria.html#drug-resistance-2",
    "href": "Malaria.html#drug-resistance-2",
    "title": "Malaria and Leishmaniasis",
    "section": "Drug resistance-2",
    "text": "Drug resistance-2"
  },
  {
    "objectID": "Malaria.html#drug-resistance-3",
    "href": "Malaria.html#drug-resistance-3",
    "title": "Malaria and Leishmaniasis",
    "section": "Drug resistance-3",
    "text": "Drug resistance-3"
  },
  {
    "objectID": "Malaria.html#outlook",
    "href": "Malaria.html#outlook",
    "title": "Malaria and Leishmaniasis",
    "section": "Outlook",
    "text": "Outlook\n## Malaria elimination and erdication"
  },
  {
    "objectID": "Malaria.html#drug-discovery-and-development-pipeline",
    "href": "Malaria.html#drug-discovery-and-development-pipeline",
    "title": "Malaria and Leishmaniasis",
    "section": "Drug discovery and development pipeline",
    "text": "Drug discovery and development pipeline"
  },
  {
    "objectID": "Malaria.html#parasitemia",
    "href": "Malaria.html#parasitemia",
    "title": "Malaria and Leishmaniasis",
    "section": "Parasitemia",
    "text": "Parasitemia\n\nParasites can be detected on light microscope examination of blood smear\n\n\n\n\n\n\n\n\n(Phillips et al., 2017c)"
  },
  {
    "objectID": "Malaria.html#cases-in-italy",
    "href": "Malaria.html#cases-in-italy",
    "title": "Malaria and Leishmaniasis",
    "section": "Cases in Italy",
    "text": "Cases in Italy\n\n“It’s the first time in my 30-year career that I’ve seen a case of malaria originating in Trentino,” said Dr Claudio Paternoster, an infectious diseases specialist at Trento’s Santa Chiara Hospital. Since the 1950s, Italy has not had a malaria problem because mosquito-infested marshes were drained. There is speculation that Sofia might have caught malaria from one of two children treated for it at the Trento hospital after 15 August. They had caught it in Africa, and recovered."
  },
  {
    "objectID": "Malaria.html#autochthonous-transmission",
    "href": "Malaria.html#autochthonous-transmission",
    "title": "Malaria and Leishmaniasis",
    "section": "Autochthonous transmission",
    "text": "Autochthonous transmission\n\n\nAirport malaria\nAsymptomatic donors from endemic aras with low-level parasitemia\n\nBlood donors\nSolid organ transplant"
  },
  {
    "objectID": "Malaria.html#cerebral-malaria",
    "href": "Malaria.html#cerebral-malaria",
    "title": "Malaria and Leishmaniasis",
    "section": "Cerebral malaria",
    "text": "Cerebral malaria\n\n\nCerebral malaria (intense sequestration of infected erythrocytes in cerebral microvessels)\nRing hemorrhages, perivascular leukocyte infiltrates, thrombin deposition\nRetinal abnormalities are common in children with characteristic features include whitening of the macula (that spares the central fovea), peripheral retina, retinal vessels, papilloedema, and multiple retinal haemorrhages\nImpairement of local delivery of oxygen and glucose\nOften does not produce neurological sequelae akin to thrombotic stroke\n\nRecovery within 48 hours common"
  },
  {
    "objectID": "Malaria.html#imaging-findings-cerebral-malaria",
    "href": "Malaria.html#imaging-findings-cerebral-malaria",
    "title": "Malaria and Leishmaniasis",
    "section": "Imaging findings cerebral malaria",
    "text": "Imaging findings cerebral malaria\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(Idro et al., 2005)"
  }
]